[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1140
1. Gyurova MS, Stancheva MZ, Arnaudova MN, Yankova RK: Intralesional bleomycin as alternative therapy in the treatment of multiple basal cell carcinomas. Dermatol Online J; 2006;12(3):25
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional bleomycin as alternative therapy in the treatment of multiple basal cell carcinomas.
  • An 82-year-old female with with multiple basal cell carcinomas is presented.
  • We injected intralesional bleomycin to eight new histologically proven basal cell cancers.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Bleomycin / administration & dosage. Carcinoma, Basal Cell / drug therapy. Neoplasms, Second Primary / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638439.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


2. Joanna R, Renata Z, Witold P, Małgorzata S, Bernaczyk P, Chyczewski L: The evaluation of human papillomavirus and p53 gene mutation in benign and malignant conjunctiva and eyelid lesions. Folia Histochem Cytobiol; 2010 Dec;48(4):530-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Papillomas and squamous cell carcinomas are the most common conjunctival and eyelid lesions.
  • Only 8.8% papillomas, 9.1% squamous cell cancers and 3.7% basal cell cancers (using PCR-RFLP method) and 26.6% papillomas, 7.4% squamous cell cancers and 9.1% basal cell cancers (using immunohisto-chemical reaction) were HPV positive. p53 gene mutation was evaluated in 24.4% papillomas, 54.5% squamous cell cancers and 22.2% basal cell cancers; most commonly in 6 and 7 exon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21478094.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


3. Peacock CD, Rudin CM: Skin deep and deeper: multiple pathways in basal cell carcinogenesis. Cancer Prev Res (Phila); 2010 Oct;3(10):1213-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin deep and deeper: multiple pathways in basal cell carcinogenesis.
  • Villani et al. define a key role for the IGF regulatory protein Igfbp2 in a genetic model of basal cell carcinogenesis driven by targeted constitutive activation of hedgehog signaling.
  • Placed in the framework of other recently published work, the observations of Villani et al. both raise questions about the cell of origin for basal cell cancers and define additional putative therapeutic and preventive targets for this disease.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Cell Transformation, Neoplastic / genetics. Hedgehog Proteins / genetics. Insulin-Like Growth Factor I / genetics. Signal Transduction / physiology. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [CommentOn] Cancer Prev Res (Phila). 2010 Oct;3(10):1222-34 [20858761.001]
  • (PMID = 20858762.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


Advertisement
4. Levi F, Randimbison L, Maspoli M, Te VC, La Vecchia C: High incidence of second basal cell skin cancers. Int J Cancer; 2006 Sep 15;119(6):1505-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of second basal cell skin cancers.
  • We considered the risk of second basal cell cancers (BCC) of the skin using a population-based series of 1,868 BCC collected between 1976 and 1985 in the Swiss Cantons of Vaud and Neuchâtel, and followed-up to the end of 2003.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasms, Second Primary / epidemiology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642479.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Kleinerman RA: Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatr Radiol; 2009 Feb;39 Suppl 1:S27-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Major advances in pediatric cancer treatment have resulted in substantial improvements in survival.
  • However, concern has emerged about the late effects of cancer therapy, especially radiation-related second cancers.
  • Studies of childhood cancer patients with inherited cancer syndromes can provide insights into the interaction between radiation and genetic susceptibility to multiple cancers.
  • Children with retinoblastoma (Rb), neurofibromatosis type 1 (NF1), Li-Fraumeni syndrome (LFS), and nevoid basal cell carcinoma syndrome (NBCCS) are at substantial risk of developing radiation-related second and third cancers.
  • A radiation dose-response for bone and soft-tissue sarcomas has been observed in hereditary Rb patients, with many of these cancers occurring in the radiation field.
  • Studies of NF1 patients irradiated for optic pathway gliomas have reported increased risks of developing another cancer associated with radiotherapy.
  • High relative risks for second and third cancers were observed for a cohort of 200 LFS family members, especially children, possibly related to radiotherapy.
  • Children with NBCCS are very sensitive to radiation and develop multiple basal cell cancers in irradiated areas.
  • [MeSH-minor] Basal Cell Nevus Syndrome / genetics. Basal Cell Nevus Syndrome / radiotherapy. Child. Humans. Li-Fraumeni Syndrome. Neurofibromatosis 1 / genetics. Neurofibromatosis 1 / radiotherapy. Radiation Dosage. Retinal Neoplasms / genetics. Retinal Neoplasms / radiotherapy. Retinoblastoma / genetics. Retinoblastoma / radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1969 Oct;71(4):747-52 [5360287.001]
  • [Cites] Health Phys. 2003 Jul;85(1):47-59 [12852471.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Br J Cancer. 1986 May;53(5):661-71 [3718823.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Cancer Res. 1988 Sep 15;48(18):5358-62 [3409256.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):959-61 [1931625.001]
  • [Cites] N Engl J Med. 1992 May 14;326(20):1309-15 [1565144.001]
  • [Cites] Radiat Res. 1995 Mar;141(3):259-77 [7871153.001]
  • [Cites] Radiat Res. 1996 May;145(5):595-601 [8619025.001]
  • [Cites] Int J Cancer. 1996 Aug 7;67(4):515-9 [8759610.001]
  • [Cites] JAMA. 1997 Oct 15;278(15):1262-7 [9333268.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 15;90(8):606-11 [9554443.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):583-93 [15667981.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2272-9 [15800318.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):271-3 [16226702.001]
  • [Cites] J Med Genet. 2006 Apr;43(4):289-94 [16155191.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2570-5 [16735710.001]
  • [Cites] Pediatr Radiol. 2006 Sep;36 Suppl 2:121-5 [16862418.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2001-6 [16642469.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 3;99(1):24-31 [17202110.001]
  • [Cites] J Med Genet. 2007 Feb;44(2):81-8 [17105749.001]
  • [Cites] Ann Neurol. 2007 Mar;61(3):189-98 [17387725.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2233-40 [17557301.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):428-36 [18334707.001]
  • [Cites] JAMA. 2008 Mar 19;299(11):1315-9 [18349092.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):228-35 [18571337.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 May;122(5):667-72 [10793343.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):431-6 [11878577.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):124-32 [12635175.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • (PMID = 19083227.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010131-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  • [Other-IDs] NLM/ NIHMS75740; NLM/ PMC2656401
  •  go-up   go-down


6. Pua VS, Huilgol S, Hill D: Evaluation of the treatment of non-melanoma skin cancers by surgical excision. Australas J Dermatol; 2009 Aug;50(3):171-5
MedlinePlus Health Information. consumer health - Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the treatment of non-melanoma skin cancers by surgical excision.
  • A retrospective study of all non-melanoma skin cancers excised by two dermatologists at a private practice in 2004 (excluding Mohs microscopic surgery cases) was conducted.
  • For basal cell cancers, the incomplete excision rate was 1.54% (5/324) and for squamous cell cancers including Bowen's disease the incomplete excision rate was 3.9% (5/129).
  • [MeSH-major] Neoplasm, Residual / pathology. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Surgical Procedures, Operative / methods
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Basal Cell / mortality. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Reoperation. Retrospective Studies. Risk Assessment. Sex Factors. South Australia. Survival Analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19659977.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


7. Campbell RM, Perlis CS, Malik MK, Dufresne RG Jr: Characteristics of Mohs practices in the United States: a recall survey of ACMS surgeons. Dermatol Surg; 2007 Dec;33(12):1413-8; discussion 1418
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Most respondents were part of a single speciality group, in a suburban or urban setting, performed between 501-1,000 cases per year, and had been in practice from 0-5 years.
  • The vast majority of Mohs excisions are for basal cell cancers and squamous cell cancers, followed by melanoma.
  • [MeSH-major] Mohs Surgery / statistics & numerical data. Professional Practice / statistics & numerical data. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2010 Feb;36(2):194-7 [20039919.001]
  • (PMID = 18076605.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Kenborg L, Jørgensen AD, Budtz-Jørgensen E, Knudsen LE, Hansen J: Occupational exposure to the sun and risk of skin and lip cancer among male wage earners in Denmark: a population-based case-control study. Cancer Causes Control; 2010 Aug;21(8):1347-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposure to the sun and risk of skin and lip cancer among male wage earners in Denmark: a population-based case-control study.
  • OBJECTIVE: We examined the association between outdoor work and the risks of non-melanoma skin cancer, cutaneous malignant melanoma, and lip cancer in a population-based case-control study.
  • METHODS: Among all male wage earners in Denmark, 42,542 cases of non-melanoma skin cancer, 7,690 cases of cutaneous malignant melanoma, and 2,341 cases of lip cancer were identified in the nationwide Danish Cancer Registry.
  • Conditional logistic regression models were used to calculate odds ratios for risks of non-melanoma skin cancer, malignant melanoma, and lip cancer in relation to outdoor work after adjusting for covariates.
  • RESULTS: For outdoor workers employed more than 10 years, the adjusted odds ratios were 0.83 (95% confidence interval (CI) 0.77-0.88) for non-melanoma skin cancer and 1.67 (95% CI 1.38-2.03) for lip cancer.
  • Significantly reduced risk of basal cell cancers on the head, trunk, upper, or lower extremities were observed (range of odds ratios, 0.36 to 0.86).
  • CONCLUSIONS: The results support the hypothesis of a decreased risk of non-melanoma skin cancer and an increased risk of lip cancer among outdoor workers in the Northern Hemisphere.
  • [MeSH-major] Lip Neoplasms / epidemiology. Melanoma / epidemiology. Occupational Exposure. Skin Neoplasms / epidemiology. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20383781.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


9. Shindel AW, Mann MW, Lev RY, Sengelmann R, Petersen J, Hruza GJ, Brandes SB: Mohs micrographic surgery for penile cancer: management and long-term followup. J Urol; 2007 Nov;178(5):1980-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mohs micrographic surgery for penile cancer: management and long-term followup.
  • PURPOSE: Mohs micrographic surgery is efficacious for the primary treatment and local recurrence control of nongenital and cutaneous squamous and basal cell cancers.
  • The efficacy of this procedure for squamous cell carcinoma of the penis was reviewed.
  • MATERIALS AND METHODS: We retrospectively reviewed the charts of all patients treated with Mohs micrographic surgery for penile cancer at our institution from 1988 to 2006.
  • A total of 13 defects were reconstructed by primary repair or granulation, 4 were reconstructed by skin grafts and 25 were reconstructed by tissue flaps and urethroplasty.
  • Two patients died, of whom 1 had no evidence of penile cancer and 1 had metastatic disease.
  • CONCLUSIONS: Mohs micrographic surgery for low stage penile cancer results in a relatively high local recurrence rate.
  • However, with repeat procedures and vigilant followup cancer specific and overall survival rates are excellent and progression rates are low.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Urol. 2008 Jul;5(7):364-5 [18521106.001]
  • (PMID = 17869306.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Smirnova IO, Kvetnoĭ IM, Anichkov NM, Smirnova ON, Antonova IV: [Mast cells in photolesion of the skin and basal cell cancer associated with it]. Arkh Patol; 2005 Sep-Oct;67(5):26-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mast cells in photolesion of the skin and basal cell cancer associated with it].
  • Morphofunctional features of skin mast cells located in the areas subjected to chronic UV-radiation and in the associated basal cell carcinoma with photoinjure have been studied.
  • It is found that chronic UV-damage leads to mast cell hyperplasia as well as activation of their synthetic, absorption and secretory functions.
  • It is suggested that mast cell hyperplasia and increase of mast cells neuroendocrine activity provide a risk of basal cell carcinoma development.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Mast Cells / radiation effects. Mastocytosis, Cutaneous / complications. Skin / pathology. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323476.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


11. Kennecke HF, Voduc D, Leung S, Cryns VL, Perou CM, Nielsen TO, Cheang M: α-basic-crystallin expression in basal-like breast cancer and its association with brain metastasis. J Clin Oncol; 2009 May 20;27(15_suppl):1025

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] α-basic-crystallin expression in basal-like breast cancer and its association with brain metastasis.
  • : 1025 Background: Basal-like breast cancers are high grade tumors with poor prognosis, having propensity for brain and lung metastasis (Perou et al.
  • Clin Cancer Res 14:1368-76, 2008, Luck et al.
  • α-basic-crystallin (αBC), a small heat shock protein with anti-apoptotic and oncogenic activity, is expressed in about half of basal-like breast cancers but only 6% of other types (Moyano et al.
  • Here we investigate the association of αBC with sites of distant metastasis in a large cohort of breast cancer patients.
  • METHODS: Our cohort consists of 4046 early invasive breast cancers referred to the British Columbia Cancer Agency from 1986 to 1992.
  • Breast cancer subtypes were defined using a surrogate of six immunohistochemical markers: ER, PR, HER2, Ki-67, epidermal growth factor receptor and cytokeratin 5/6.
  • Basal-like tumors with brain metastasis commonly co-expressed αBC (Chi-square p=0.006).
  • CONCLUSION: αBC is significantly associated with brain metastasis, particularly among basal breast cancers.
  • These findings suggested that αBC may be involved in tumor cell metastasis and may allow early identification of a subset of patients at particularly high risk of brain metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961038.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Ray PS, Wang J, Qu Y, Shin-Sim M, Shamonki J, Liu B, Hoon DS, Giuliano AE, Cui X: Role of FOXC1 in regulation of basal-like/triple-negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):11016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of FOXC1 in regulation of basal-like/triple-negative breast cancer.
  • : 11016 Background: Class identification studies have proposed 3 prognostically relevant molecular subtypes of breast cancer: luminal, HER2 and basal-like.
  • We hypothesized a direct correlation between FOXC1 expression and basal-like breast cancer.
  • METHODS: Expression of FOXC1, CK5, CK14, EGFR, c-Kit, αB-crystallin, ITGB4 and FOXC2 in basal-like breast cancer was examined using publicly available microarray datasets.
  • FOXC1 protein expression was assessed by immunohistochemistry (IHC) of a 96-sample breast cancer tissue microarray.
  • Normal breast epithelial, luminal and basal breast cancer cells transfected with FOXC1 vectors were evaluated for cell proliferation, migration and invasion.
  • RESULTS: FOXC1 was found to be consistently and exclusively upregulated in basal-like triple negative breast cancer and was associated with poor overall survival (p<0.0001).
  • The FOXC1 gene signature accurately predicted the basal-like phenotype.
  • IHC analysis of FOXC1 protein expression in human breast cancers confirmed its potential to be used as a clinical biomarker of basal-like breast cancer.
  • Normal breast epithelial cells and luminal breast cancer cells with low or no FOXC1 expression underwent epithelial-to-mesenchymal transition and displayed increased cellular proliferation, migration, invasion, and expression of basal cell markers when FOXC1 was overexpressed.
  • In contrast, knockdown of FOXC1 by shRNA in basal-like breast cancer cells conferred luminal phenotype.
  • Breast cancer progression-linked signaling pathways like NF-κB and p38MAPK were significantly stimulated in basal-like breast cancer as well as by in vitro FOXC1 overexpression.
  • CONCLUSIONS: FOXC1 is a dominant determinant of the basal-like phenotype of breast cancer.
  • We propose FOXC1 to be the single best molecular marker of and a potential therapeutic target for basal-like / triple negative breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963979.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Hanker LC, Karn T, Rody A, Ruckhäberle E, Solbach C, Kaufmann M: Prognostic value of gene expression of p63 by microarray analysis in estrogen receptor positive and negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of gene expression of p63 by microarray analysis in estrogen receptor positive and negative breast cancer.
  • P63 is overexpressed in many different tumors like head and neck cancer, lung cancers, uterine tumors and breast cancer, and has been associated with poor prognosis in some studies.
  • P63 was found to be overexpressed in a subset of highly aggressive breast cancers that represent a basal and myoepithelial phenotype and have a poor clinical outcome.
  • This protein seems to be a specific myoepithelial cell marker in normal breast tissue and might represent a prognostic factor in breast cancer.
  • METHODS: Large scale analysis was performed using Affymetrix microarray data from n=1581 breast cancer patients to evaluate p63 expression.
  • High expression of p63 was significantly associated with longer OS in both ER negative (n = 334, log rank p = 0.022) and ER positive (n = 929, log rank p < 0,001) breast cancer.
  • CONCLUSIONS: P63 expression is a prognostic factor in both ER positive and negative breast cancer and could be helpful for risk assessment in breast cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960724.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Iwase H, Yamamoto Y, Kurebayashi J, Tsuda H, Ota T, Kurosumi M, Miyamoto K, Iwase T, Research Group of the Japanese Breast Cancer Society: Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e22122

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases.
  • : e22122 Background: Triple-negative (TN) breast cancers which are negative for ER, PgR, and HER2 by immunohistochemistry are associated with a poor prognosis.
  • To clarify the characteristics of TN tumors, the data of the registration committee of the Japanese Breast Cancer Society were analyzed with respect to clinicopathologic factors, response to neoadjuvant chemotherapy (NAC) and prognosis.
  • TN cancers were diagnosed at a slightly advanced stage and more of the cases had lymph node metastases compared to other types.
  • Squamous cell, spindle cell carcinoma, or metaplastic carcinoma with bone/cartilage metaplasia was found in only TN type.
  • Central reviews of immunohistochemistry, such as ER, PgR, HER2, CK5/6, EGFR etc, will be confirmed in this cohort, for TN tumors are similar to basal-like tumors discriminated by gene- profiling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963560.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Jirakulaporn T, Mathew J, Lindgren BR, Dudek AZ: Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol; 2009 May 20;27(15_suppl):1519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR).
  • : 1519 Background: Skin cancers are the most common malignancies in OTR.
  • Topical 5% 5-FU has been used to successfully treat squamous cell carcinoma (SCC) in situ and actinic keratosis (AK).
  • Capecitabine, an orally-administered prodrug of 5-FU, in combination with interferon was shown to be effective in the treatment of advanced SCC of the skin.
  • This study was to determine the efficacy of low-dose capecitabine in secondary prevention of the skin cancers in OTR.
  • METHODS: OTR who developed recurrent skin cancers, SCC, and/or basal cell carcinoma (BCC), were given low-dose capecitabine 1g/m2 divided in two daily doses, day 1-14 of 21-day treatment cycle.
  • Skin surveillances were performed by dermatologists every 1 to 3 months.
  • Age and the number of transplants were not significantly related to the change in incidence rates for all skin lesion types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR: Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol; 2006 Feb;126(2):422-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small amounts of cell-free DNA circulate in both healthy and diseased human blood, while increased concentrations of DNA are present in the serum of cancer patients.
  • For comparison, sera from patients with other skin tumors (nine basal cell cancers, five Kaposi's sarcoma), different metastasized cancers (five breast cancers, five colon cancers), and several chronic inflammatory diseases (n = 12) were also analyzed.
  • [MeSH-major] DNA Methylation. Epigenesis, Genetic. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Melanoma / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374457.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Intracellular Signaling Peptides and Proteins; 0 / RASSF1 protein, human; 0 / Repressor Proteins; 0 / SOCS1 protein, human; 0 / SOCS2 protein, human; 0 / Suppressor of Cytokine Signaling Proteins; 0 / Tumor Suppressor Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


17. McNaughton SA, Marks GC, Green AC: Role of dietary factors in the development of basal cell cancer and squamous cell cancer of the skin. Cancer Epidemiol Biomarkers Prev; 2005 Jul;14(7):1596-607
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of dietary factors in the development of basal cell cancer and squamous cell cancer of the skin.
  • The role of dietary factors in the development of skin cancer has been investigated for many years; however, the results of epidemiologic studies have not been systematically reviewed.
  • This article reviews human studies of basal cell cancer (BCC) and squamous cell cancer (SCC) and includes all studies identified in the published scientific literature investigating dietary exposure to fats, retinol, carotenoids, vitamin E, vitamin C, and selenium.
  • There is insufficient evidence on which to make a judgment about an association of other carotenoids with skin cancer.
  • Many of the existing studies contain limitations, however, and further well-designed and implemented studies are required to clarify the role of diet in skin cancer.
  • Additionally, the role of other dietary factors, such as flavonoids and other polyphenols, which have been implicated in skin cancer development in animal models, needs to be investigated.
  • [MeSH-major] Carcinoma, Basal Cell. Carcinoma, Squamous Cell. Diet. Dietary Fats. Skin Neoplasms. Vitamins

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vitamins.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030089.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Vitamins
  • [Number-of-references] 62
  •  go-up   go-down


18. Evke E, Minbay FZ, Temel SG, Kahveci Z: Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval. J Mol Histol; 2009 Feb;40(1):13-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval.
  • p53 is the most frequently altered tumor-suppressor gene in skin cancer.
  • This study was designed to evaluate the efficacy of different fixatives, of microwaving and microwave pretreatment method to retrieve p53 immunoreactivity in paraffin-embedded non-lesioned (adjacent normal tissue) human skin samples or pathological human skin samples diagnosed as basal cell carcinoma.
  • In this study the effects of six different fixation methods on the immunohistochemical staining have been investigated in basal cell tumor specimens.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Immunohistochemistry / methods. Microwaves. Skin Neoplasms / metabolism. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096907.001).
  • [ISSN] 1567-2387
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 1HG84L3525 / Formaldehyde; 3K9958V90M / Ethanol
  •  go-up   go-down


19. Moosa MR: Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation. Medicine (Baltimore); 2005 Jan;84(1):12-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From April 1976 through March 1999, 41 (7.6%) patients were diagnosed with cancer among a heterogeneous population of renal allograft recipients treated at our institution in Cape Town, South Africa.
  • However, squamous cell cancer and basal cell cancer of the skin (in that order) were the most common cancers in white patients, in whom they occurred exclusively.
  • On the other hand, Kaposi sarcoma was the most common cancer in nonwhite renal allograft recipients, in whom it accounted for almost 80% of all cancers.
  • Review of the world literature suggests that posttransplant cancers are less common in developing countries; Kaposi sarcoma is the most common lesion, with few exceptions.
  • In general, cyclosporine is not associated with a significant increase in the incidence of cancer after renal transplantation, although the time to the first cancer may be reduced.
  • In our experience, the pattern of posttransplant cancers in white and nonwhite patients living in the same geographic region epitomizes the world experience of the disease and suggests that genetic factors, rather than geography, are the more important determinants of cancer development after renal transplantation.
  • [MeSH-minor] Adult. Epidemiologic Methods. Female. Global Health. Humans. Immunosuppression / adverse effects. Male. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / ethnology. Sarcoma, Kaposi / etiology. Skin Neoplasms / epidemiology. Skin Neoplasms / ethnology. Skin Neoplasms / etiology. South Africa / epidemiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15643296.001).
  • [ISSN] 0025-7974
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


20. Rudin CM: Beyond the scalpel: targeting hedgehog in skin cancer prevention. Cancer Prev Res (Phila); 2010 Jan;3(1):1-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond the scalpel: targeting hedgehog in skin cancer prevention.
  • This perspective places the article by Tang et al. in this issue of the journal (beginning on page 25) in the context of recent work defining the hedgehog signaling pathway as a central etiologic factor and as a therapeutic target in basal cell cancer.
  • Tang et al. show that inhibition of cyclooxygenase activity, either genetically (in a relevant mouse model) or pharmacologically (in the mouse and in patients highly predisposed to develop basal cell skin cancers), may suppress basal cell carcinogenesis.
  • This new study of cyclooxygenase inhibition, together with recent data on the efficacy of hedgehog pathway inhibition, offers new hope for patients at a high risk for basal cell cancer.
  • [MeSH-major] Carcinoma, Basal Cell / prevention & control. Hedgehog Proteins / metabolism. Signal Transduction / physiology. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Prev Res (Phila). 2010 Jan;3(1):25-34 [20051370.001]
  • (PMID = 20051365.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hedgehog Proteins
  • [Number-of-references] 17
  •  go-up   go-down


21. Moskalik K, Kozlov A, Demin E, Boiko E: The efficacy of facial skin cancer treatment with high-energy pulsed neodymium and Nd:YAG lasers. Photomed Laser Surg; 2009 Apr;27(2):345-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of facial skin cancer treatment with high-energy pulsed neodymium and Nd:YAG lasers.
  • OBJECTIVE: The aim of this study was to assess the curative and cosmetic efficacy of treatment for facial skin cancer using neodymium laser irradiation.
  • BACKGROUND DATA: Due to the complex anatomy of the area, therapy for facial skin cancer is difficult.
  • MATERIALS AND METHODS: Laser irradiation was used for the treatment of 3461 patients with 3624 facial skin cancer lesions of stages T(1-2)N(0)M(0:) 3346 basal cell skin cancers, 188 limited basal cell skin cancer recurrences, and 90 squamous cell skin cancers.
  • RESULTS: Patients with basal cell skin cancer treated by irradiation with the Nd laser developed recurrences in 1.8% of cases, and patients treated with the Nd:YAG laser had a recurrence rate of 2.5%.
  • Recurrences following treatment for basal cell skin cancer, and those of squamous cell skin cancer, after irradiation with the Nd laser appeared in 3.7% and 4.4% of patients, respectively.
  • Overall, the frequency of facial skin cancer recurrences after treatment with laser irradiation was 2.1% of all the irradiated tumors.
  • CONCLUSION: Neodymium laser irradiation is an effective method to treat facial skin cancer of stages T(1-2)N(0)M(0), and results in acceptable cosmetic results.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Facial Neoplasms / radiotherapy. Skin Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Facial Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19382838.001).
  • [ISSN] 1557-8550
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Campbell RM, Barrall D, Wilkel C, Robinson-Bostom L, Dufresne RG Jr: Post-Mohs micrographic surgical margin tissue evaluation with permanent histopathologic sections. Dermatol Surg; 2005 Jun;31(6):655-8; discussion 658
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Incomplete resection of nonmelanoma skin cancer is associated with a relatively high rate of recurrent tumors.
  • Mohs micrographic surgery provides microscopic evaluation of tumor margins to ensure complete excision of nonmelanoma skin cancers at high risk of recurrence.
  • OBJECTIVE: This purpose of this study is to confirm the histologic accuracy of Mohs excision of facial skin cancers by evaluating an additional layer of tissue with permanent histopathologic sections after Mohs excision.
  • RESULTS: Two excisions of nodular basal cell cancer were determined by the pathologist to have positive tumor involvement on post-Mohs permanent tissue.
  • On additional review, one specimen was interpreted to be more consistent with follicular epithelium, and the second was verified as a focus of nodular basal cell cancer.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Facial Neoplasms / surgery. Mohs Surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasms, Adnexal and Skin Appendage / surgery. Postoperative Period. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2006 Mar;32(3):463 [16640701.001]
  • (PMID = 15996415.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kovacevic PT, Visnjic MM, Kovacevic TT, Radojkovic MR, Stojanovic MR: Extended orbital exenteration in the treatment of advanced periocular skin cancer with primary reconstruction with a galeacutaneous flap. Scand J Plast Reconstr Surg Hand Surg; 2009;43(6):325-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended orbital exenteration in the treatment of advanced periocular skin cancer with primary reconstruction with a galeacutaneous flap.
  • Skin cancers (basal cell cancer and squamous cell skin cancer) arising in the periorbital region could present as invasive tumours infiltrating the orbit and orbital walls.
  • We describe the treatment of advanced invasive skin cancers of the periorbital region by extended orbital exenteration.
  • Twenty postoperative defects were reconstructed using galea-skin flaps, and one defect was left to heal by secondary intention.
  • The reconstruction with frontal or frontoparietal galea-skin flap is a suitable option.
  • The secondary defect can be closed primarily or by skin grafting.
  • Extended orbital exenteration offers the best chances of cure in the treatment of non-melanotic skin cancers that have infiltrated the orbit and orbital walls.

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19995251.001).
  • [ISSN] 1651-2073
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Simka M: Do nonmelanoma skin cancers develop from extra-cutaneous stem cells? Int J Cancer; 2008 May 15;122(10):2173-7
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do nonmelanoma skin cancers develop from extra-cutaneous stem cells?
  • A hypothesis is presented that nonmelanoma skin cancers can develop from extra-cutaneous stem cells, and not exclusively from skin keratinocytes.
  • This idea is supported by recent findings regarding the initiation of cancers in the digestive tract, and by a cancer stem cell model of a neoplasia.
  • Some epidemiological data and recent findings regarding mechanisms of wound healing indicate that skin cancers could also originate from bone marrow-derived or other extra-cutaneous stem cells in addition to local stem cells.
  • Furthermore, in chronically inflamed skin, or in an immunodeficient patient, malignant transformation of extra-cutaneous stem cells is more likely to occur.
  • There is one well-documented case of basal cell cancer which has arisen from donor cells in a kidney transplant recipient, but it remains unclear if this cancer developed directly from a donor-derived cell, or via fusion of such cells with premalignant keratinocytes.
  • Hopefully, combining animal models of skin cancer initiation with experiments exploring the role of bone marrow-derived cells in skin healing will bring to light the exact mechanism of carcinogenesis of nonmelanoma skin cancers.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Skin Neoplasms / etiology. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18240148.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  •  go-up   go-down


25. Wietfeldt ED, Thiele J: Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg; 2009 May;22(2):127-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies of the anal margin and perianal skin.
  • Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies.
  • Commonly included in this group of cancers are Bowen's disease (intraepithelial squamous cell cancer), perianal Paget's disease (intraepithelial adenocarcinoma), invasive squamous cell cancer, basal cell cancer, and malignant melanoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • (PMID = 20436838.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780245
  • [Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
  •  go-up   go-down


26. Buell JF, Hanaway MJ, Thomas M, Alloway RR, Woodle ES: Skin cancer following transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc; 2005 Mar;37(2):962-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer following transplantation: the Israel Penn International Transplant Tumor Registry experience.
  • The purpose of this study was to analyze a large series of skin cancers in solid organ transplant recipients to determine their biologic behavior.
  • METHODS: A retrospective review of all US transplant recipients with skin cancer reported to the Israel Penn International Transplant Tumor Registry was performed.
  • RESULTS: Transplant recipients from the United States with skin malignancies were identified (n = 2018) and assigned to 1 of 3 groups: squamous cell cancer (SCC), basal cell cancer (BCC), or combined malignancies (BCC/SCC).
  • Squamous cell to basal cell cancer ratio was found to be 1.9 to 1.
  • The median interval from transplant to skin cancer diagnosis was greater than 4 years in each group and longest in those with isolated SCC lesions.
  • Cancer-specific deaths were significantly higher in the SCC (8%) and BCC/SCC (6.8%) groups compared to the BCC (3.6%) group.
  • [MeSH-major] Registries. Skin Neoplasms / epidemiology. Transplantation / adverse effects
  • [MeSH-minor] Carcinoma, Squamous Cell / epidemiology. Humans. Neoplasms, Basal Cell / epidemiology. Postoperative Complications / epidemiology. Recurrence. Retrospective Studies. Time Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848591.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


27. Gallagher RP, Lee TK, Bajdik CD, Borugian M: Ultraviolet radiation. Chronic Dis Can; 2010;29 Suppl 1:51-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The International Agency for Research on Cancer has noted that there is sufficient evidence from studies in animals and in man to establish ultraviolet radiation as a human carcinogen.
  • Skin cancer has been the most commonly studied cancer site with respect to UV radiation.
  • The nature and timing of sun exposure appear to be important determinants of both the degree of risk and the type of skin cancer.
  • Cutaneous malignant melanoma and basal cell cancer are much more strongly related to measures of intermittent ultraviolet exposure (particularly those of childhood or adolescence) than to measures of cumulative exposure.
  • In contrast, squamous cell cancer is more strongly related to constant or cumulative sun exposure.
  • Lip cancer is causally related to lifetime sun exposure.
  • It has been estimated that solar ultraviolet radiation accounts for approximately 93 percent of skin cancers and about half of lip cancers.
  • This translates to approximately 4,500 life-threatening cancers (cutaneous malignant melanoma) per year in Canada, as well as 65,000 less serious cancers (basal cell cancer, squamous cell cancer and lip cancer).
  • Several recent studies suggest a possible inverse relationship between ultraviolet radiation exposure and risk of non-Hodgkin lymphoma, colon, breast and prostate cancer, and investigators have speculated that this might be due to the higher serum levels of vitamin D stimulated by high lifetime sun exposure.
  • Further, studies conducted within cohorts using stored pre-diagnostic serum suggest that those with high levels of vitamin D have lower incidence rates of a number of malignancies, particularly colon cancer.
  • However, since serum vitamin D levels can be raised through the use of supplements without increasing risk for skin lip and other known UV-related cancers, changes to health policy with regard to exposure are not merited at this point.
  • [MeSH-major] Carcinoma, Basal Cell. Carcinoma, Squamous Cell. Melanoma. Skin Neoplasms. Sunlight / adverse effects. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21199599.001).
  • [ISSN] 1481-8523
  • [Journal-full-title] Chronic diseases in Canada
  • [ISO-abbreviation] Chronic Dis Can
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


28. Ahokas K, Skoog T, Suomela S, Jeskanen L, Impola U, Isaka K, Saarialho-Kere U: Matrilysin-2 (matrix metalloproteinase-26) is upregulated in keratinocytes during wound repair and early skin carcinogenesis. J Invest Dermatol; 2005 Apr;124(4):849-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrilysin-2 (matrix metalloproteinase-26) is upregulated in keratinocytes during wound repair and early skin carcinogenesis.
  • We studied its role in benign skin disorders characterized by epithelial proliferation, in wound repair, skin cancer, and regulation in keratinocyte (KC) cultures.
  • MMP-26 is expressed by laminin-5-positive KC in the migrating area during wound repair, in benign skin disorders characterized by inflammation and microdisruptions of basement membrane, but in intact skin only in hair follicles.
  • It was detected in occasional atypical KC in pre-malignant lesions but not in basal cell cancer islands.
  • Although MMP-26 was expressed in grades I and II squamous cell cancers (SCC), it was not present in dedifferentiated grade III tumors.
  • In KC and HaCaT cell cultures, 12-phorbol-13-myristate-acetate, epidermal growth factor, tumor necrosis factor-alpha, transforming growth factor-beta1, interleukin-1 (IL-1)beta, IL-6, insulin-like growth factor, gamma-IFN, retinoic acid, dexamethasone, four matrices or ras-transformation were unable to upregulate MMP-26 expression.
  • The expression pattern of MMP-26 suggests that it may be upregulated in basal KC even without tumorigenesis because of altered cell-matrix interactions and inflammation and, unlike most MMP, becomes downregulated during histological dedifferentiation of SCC.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / physiopathology. Keratinocytes / physiology. Matrix Metalloproteinases / genetics. Skin Neoplasms / physiopathology
  • [MeSH-minor] Cell Line, Transformed. Cell Line, Tumor. Gene Expression Regulation, Neoplastic. Humans. Matrix Metalloproteinases, Secreted. Up-Regulation. Wound Healing / physiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816845.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.- / MMP26 protein, human; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases, Secreted
  •  go-up   go-down


29. Sahin B, Ozdemir R, Kocer U, Cologlu H, Kayiran O, Oruc M: Multi-centric basal and squamous cell skin malignancies of the craniofacial region. J Craniofac Surg; 2006 Mar;17(2):265-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-centric basal and squamous cell skin malignancies of the craniofacial region.
  • The etiology of skin malignancies is evaluated as multi-factorial.
  • Twenty-seven patients with multi-centric skin malignancies investigated as if having predisposing syndromes.
  • The etiological factors and the classification of skin malignancies are assessed.
  • Four out of 27 patients having multi-centric skin malignancies were realized as syndromic.
  • Ninety-eight areas were distinguished as having skin malignancies in 27 patients.
  • Of the 98 malignancies, 24 were squamous cell cancer, 67 were basal cell cancer, and seven were basosquamous cell cancer pathologically.
  • Wound closures were carried out as primarily in 39 excisions; using skin grafts in 21 excisions, local flaps in 28 excisions, and distant flap procedures in 10 regions.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Head and Neck Neoplasms / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Disease Susceptibility. Female. Humans. Male. Middle Aged. Risk Factors. Skin Transplantation. Sunlight / adverse effects. Surgical Flaps. Xeroderma Pigmentosum / complications

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633173.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Aarts MJ, van der Aa MA, Coebergh JW, Louwman WJ: Reduction of socioeconomic inequality in cancer incidence in the South of the Netherlands during 1996-2008. Eur J Cancer; 2010 Sep;46(14):2633-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of socioeconomic inequality in cancer incidence in the South of the Netherlands during 1996-2008.
  • BACKGROUND: Cancer incidence varies according to socioeconomic status (SES) and time trends.
  • PATIENTS AND METHODS: We studied patients diagnosed in 1996-2008 and registered in the South Netherlands Cancer registry.
  • RESULTS: People with a low SES exhibited elevated incidence rates of cancer of the head and neck, upper airways (both sexes), gastro-intestinal tract, squamous cell skin cancer, breast (> or =65) and all female genital, bladder, kidney and mature B-cells (all in females only), whereas prostate cancer, basal cell skin cancer (BCC) and melanoma (both except in older females) were most common among those with a high SES.
  • Due to the greater increase in prostate cancer and melanoma in high SES males and the larger reduction of lung cancer in low SES males, incidence of all cancers combined became more elevated among males of > or =45 years with a high and intermediate SES, and approached rates for low SES men aged 45-64.
  • In spite of more marked increases in the incidence of colon, rectal and lung cancer in high SES women, the incidence of all cancers combined remained highest for low SES women of > or =45 years.
  • However, at age 25-44 years, the highest incidence of cancer of the breast and melanoma was observed among high SES females.
  • During 1996-2008 inequalities increased unfavourably among higher SES people for prostate cancer, BCC (except in older women) and melanoma (at middle age), while decreasing favourably among low SES people for cancers of the oesophagus, stomach, pancreas and kidney (both in females only), breast (> or =65 years), corpus uteri and ovary.
  • CONCLUSIONS: Although those with a low SES exhibited the highest incidence rates of the most common cancers, higher risks were observed among those with high SES for melanoma and BCC (both except older females) and for prostate and breast (young females) cancer.
  • Altogether this might also have contributed to the recent higher cancer awareness in Dutch society which is usually promoted more by patients of high SES and those who know or surround them.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20843492.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


31. Micke P, Ostman A: Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets; 2005 Dec;9(6):1217-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy.
  • Stroma cells contribute to the microenvironment that is essential for cancer growth, invasion and metastatic progression.
  • Fibroblasts, often termed myofibroblasts or cancer-associated fibroblasts (CAFs), represent the most abundant cell type in the tumour stroma.
  • Recently, novel global methods for gene expression profiling were applied to comprehensively characterise CAFs from breast, pancreas, colon and basal cell cancer in their in situ environment.
  • [MeSH-minor] Animals. Cell Proliferation. Humans

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300472.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 147
  •  go-up   go-down


32. Diffey B: Sunscreens: expectation and realization. Photodermatol Photoimmunol Photomed; 2009 Oct;25(5):233-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From a public health perspective, the desire to prevent sunburn and protect against skin cancer are the two major drivers for using sunscreen.
  • Sunscreens have been shown to be effective in reducing the incidence of squamous cell cancer and with promising benefits for basal cell cancer.
  • [MeSH-minor] Humans. Skin Neoplasms / prevention & control. Sunburn


33. Olmedo JM, Warschaw KE, Schmitt JM, Swanson DL: Optical coherence tomography for the characterization of basal cell carcinoma in vivo: a pilot study. J Am Acad Dermatol; 2006 Sep;55(3):408-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical coherence tomography for the characterization of basal cell carcinoma in vivo: a pilot study.
  • OBJECTIVE: The purpose of this pilot study was to define and characterize basal cell carcinoma by using optical coherence tomography.
  • METHODS: Twenty-three patients with 49 lesions clinically suggestive of superficial basal cell carcinoma were recruited.
  • RESULTS: Basal cell carcinoma was identified in 27 patients; all 27 had optical coherence tomographic images for comparison.
  • Of the remainder, 20 sites matched the histologic features seen on light microscopy, with excellent correlation between optical coherence tomographic images and histopathologic features of superficial, nodular, micronodular and infiltrative basal cell carcinomas.
  • CONCLUSIONS: Optical coherence tomography technology has potential for the diagnosis and histopathologic characterization of basal cell cancer.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Skin Neoplasms / diagnosis. Tomography, Optical Coherence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908344.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Jovanović M, Brasanac D, Rasulić L, Colić M, Stojicić M, Malis M: [The excision width in surgical treatment of basal cell carcinoma]. Acta Chir Iugosl; 2006;53(3):53-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The excision width in surgical treatment of basal cell carcinoma].
  • Basal cell carcinoma originates from pluripotent cells of basal layer of epiderm, external covering of hair follicles, sebaceous glands or other skin adnexa.
  • There are several types of basal cell carcinomas that may be manifested in over 12 clinical forms.
  • The analysis included 250 patients of both gender and different age, operated for basal cell carcinoma.
  • Clinical characteristics of basal cell carcinoma and the width of the excision were described.
  • It was concluded that the width of the excision of basal cell cancer was in relation to histological type.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338201.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


35. Yan T, Angelini M, Alman BA, Andrulis IL, Wunder JS: Patched-one or smoothened gene mutations are infrequent in chondrosarcoma. Clin Orthop Relat Res; 2008 Sep;466(9):2184-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some tumors exhibiting hedgehog pathway activation such as basal cell cancer frequently harbor PATCHED-ONE (PTCH-1) or SMOOTHENED (SMO) gene mutations.
  • [MeSH-major] Bone Neoplasms / genetics. Chondrosarcoma / genetics. Receptors, Cell Surface / genetics. Receptors, G-Protein-Coupled / genetics

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2007 Nov 8;450(7167):252-8 [17960137.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):129-34 [8906787.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):44-51 [10564585.001]
  • [Cites] Lab Invest. 2000 Dec;80(12):1925-34 [11140704.001]
  • [Cites] Nat Genet. 2002 Mar;30(3):306-10 [11850620.001]
  • [Cites] Nature. 2002 May 16;417(6886):299-304 [12015606.001]
  • [Cites] Development. 2002 Jun;129(12):2977-86 [12050144.001]
  • [Cites] J Endocrinol. 2002 Aug;174(2):R1-6 [12176676.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):198-204 [12360027.001]
  • [Cites] Dev Cell. 2002 Sep;3(3):439-49 [12361605.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4616-21 [12679522.001]
  • [Cites] Nature. 2003 May 15;423(6937):332-6 [12748651.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] J Pathol. 2004 Jan;202(1):113-20 [14694528.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Genomics. 1989 Nov;5(4):874-9 [2687159.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4562-5 [8840960.001]
  • [Cites] Nat Clin Pract Rheumatol. 2007 Oct;3(10):580-9 [17906613.001]
  • [Cites] Am J Hum Genet. 1997 Jan;60(1):21-6 [8981943.001]
  • [Cites] Trends Genet. 1997 Jan;13(1):14-21 [9009843.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):833-6 [9989836.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]
  • [Cites] Hum Mutat. 2004 Dec;24(6):466-73 [15523647.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):43-51 [15656799.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 18;328(3):658-65 [15694399.001]
  • [Cites] J Pathol. 2005 Mar;205(4):476-82 [15685701.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):2990-2 [15833820.001]
  • [Cites] J Pathol. 2005 Jun;206(2):143-50 [15834844.001]
  • [Cites] Cancer Lett. 2005 Sep 28;227(2):99-104 [16112412.001]
  • [Cites] J Pathol. 2006 Jan;208(1):17-25 [16294371.001]
  • [Cites] Am J Pathol. 2006 Jan;168(1):321-30 [16400033.001]
  • [Cites] Hum Mutat. 2006 Mar;27(3):215-9 [16419085.001]
  • [Cites] Orphanet J Rare Dis. 2006;1:37 [16995932.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):1046-55 [16909105.001]
  • [Cites] Nat Cell Biol. 2007 Sep;9(9):1005-9 [17762891.001]
  • [ErratumIn] Clin Orthop Relat Res. 2009 Dec;467(12):3356
  • (PMID = 18543049.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / SMO protein, human; 0 / patched receptors
  • [Other-IDs] NLM/ PMC2492993
  •  go-up   go-down


36. Wolff T, Tai E, Miller T: Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med; 2009 Feb 3;150(3):194-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force.
  • BACKGROUND: Skin cancer is the most commonly diagnosed cancer in the United States.
  • The majority of skin cancer is nonmelanoma cancer, either basal cell cancer or squamous cell cancer.
  • The incidence of both melanoma and nonmelanoma skin cancer has been increasing over the past 3 decades.
  • Preventive Services Task Force (USPSTF) found insufficient evidence to recommend for or against routine screening for skin cancer by using whole-body skin examination for early detection of skin cancer.
  • PURPOSE: To update the evidence of benefits and harms of screening for skin cancer in the general population.
  • STUDY SELECTION: English-language studies were selected to answer the following key question: Does screening in asymptomatic persons with whole-body examination by a primary care clinician or by self-examination reduce morbidity and mortality from skin cancer?
  • Randomized, controlled trials and case-control studies of screening for skin cancer were selected.
  • One author selected English-language studies to answer the following contextual questions: Can screening with whole-body examination by primary care clinicians or by self-examination accurately detect skin cancer?
  • DATA SYNTHESIS: No new evidence from controlled studies was found that addressed the benefit of screening for skin cancer with a whole-body examination by a physician.
  • One article of fair quality, which reanalyzed data from a 1996 study identified for the 2001 report for the USPSTF, provides limited but insufficient evidence on the benefit of skin self-examination in the reduction of morbidity and mortality from melanoma.
  • LIMITATIONS: Direct evidence linking skin cancer screening to improved health outcomes is lacking.
  • CONCLUSION: The limited evidence prevents accurate estimation of the benefits of screening for skin cancer in the general primary care population.
  • [MeSH-major] Mass Screening. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomedical Research. Early Detection of Cancer. Evidence-Based Medicine. Female. Humans. Male. Primary Health Care. Risk Assessment. Self-Examination

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2010 Mar;146(3):322-4 [20231506.001]
  • [SummaryForPatientsIn] Ann Intern Med. 2009 Feb 3;150(3):I40 [19189902.001]
  • (PMID = 19189909.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


37. Ahmed SU, Milner J: Basal cancer cell survival involves JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network. PLoS One; 2009;4(10):e7305
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cancer cell survival involves JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network.
  • BACKGROUND: The regulation of apoptosis under basal (non-stress) conditions is crucial for normal mammalian development and also for normal cellular turnover in different tissues throughout life.
  • Deficient regulation of basal apoptosis, or its perturbation, can result in impaired development and/or disease states including cancer.
  • In contrast to stress-induced apoptosis the regulation of apoptosis under basal conditions is poorly understood.
  • To address this issue we have compared basal- and stress-induced apoptosis in human epithelial cells of normal and cancerous origins.
  • METHODOLOGY/PRINCIPAL FINDINGS: Combinatorial RNAi plus gene knockout were employed to access and map basal regulatory pathways of apoptosis.
  • We demonstrate that basal apoptosis is constitutively suppressed by JNK2 in a range of human cancer cell lines.
  • This effect was not observed in non-cancer cells.
  • Silencing JNK2 by RNAi resulted in JNK1-dependent apoptosis of cancer cells via up-regulation of the AP-1 factor c-Jun.
  • Unexpectedly we discovered that JNK1 and c-Jun promote basal apoptosis in the absence of "activating phosphorylations" typically induced by stress.
  • Basal apoptosis was mediated by components of the TNFalpha response pathway but was mechanistically distinct from TNFalpha-induced apoptosis.
  • CONCLUSIONS/SIGNIFICANCE: Our results demonstrate that mechanistically distinct pathways operate to regulate apoptosis in mammalian cells under basal (physiological) versus stress-induced conditions.
  • We also describe a novel apoptotic network which governs the basal survival of cancer cells.
  • This information also opens new avenues for therapeutic intervention in human proliferative disease states including cancer.
  • [MeSH-minor] Cell Line, Tumor. Cell Survival. Gene Silencing. Humans. NF-kappa B / metabolism. Neoplasms / metabolism. Phosphorylation. RNA Interference. Tumor Necrosis Factor-alpha / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):6887-900 [12972607.001]
  • [Cites] EMBO J. 2003 Aug 1;22(15):3876-86 [12881422.001]
  • [Cites] Mol Cell. 2004 Sep 10;15(5):713-25 [15350216.001]
  • [Cites] Cell. 1990 Mar 23;60(6):991-7 [2180580.001]
  • [Cites] Nature. 1991 Oct 17;353(6345):670-4 [1922387.001]
  • [Cites] Mol Cell Biol. 1992 Aug;12(8):3507-13 [1630458.001]
  • [Cites] Nature. 1992 Aug 13;358(6387):597-9 [1501714.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):339-42 [1406939.001]
  • [Cites] Genes Dev. 1993 Nov;7(11):2135-48 [8224842.001]
  • [Cites] Exp Eye Res. 1996 Feb;62(2):155-69 [8698076.001]
  • [Cites] Cell. 1996 Nov 1;87(3):565-76 [8898208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7337-42 [9207092.001]
  • [Cites] Annu Rev Immunol. 1998;16:225-60 [9597130.001]
  • [Cites] Genes Dev. 1998 Sep 1;12(17):2658-63 [9732264.001]
  • [Cites] Science. 1998 Nov 20;282(5393):1497-501 [9822382.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2092-5 [9851932.001]
  • [Cites] J Cell Sci. 2004 Dec 1;117(Pt 25):5965-73 [15564374.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):298-305 [15768047.001]
  • [Cites] Cancer Cell. 2005 Jul;8(1):25-33 [16023596.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1717-22 [16446428.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):425-34 [16766262.001]
  • [Cites] Mol Cell. 2006 Sep 15;23(6):899-911 [16973441.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5754-62 [17575142.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):297-303 [17591974.001]
  • [Cites] Front Biosci. 2008;13:2774-83 [17981752.001]
  • [Cites] Cell Cycle. 2007 Nov 1;6(21):2669-77 [17957139.001]
  • [Cites] Cell Signal. 2008 May;20(5):862-71 [18295447.001]
  • [Cites] Cell. 2008 May 16;133(4):577-80 [18485866.001]
  • [Cites] Cell Cycle. 2008 Oct;7(19):3091-7 [18838864.001]
  • [Cites] Nat Rev Cancer. 2009 Feb;9(2):123-8 [19132007.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8469-78 [10567572.001]
  • [Cites] Mol Cell Biol. 2000 May;20(10):3407-16 [10779330.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):37-40 [11242034.001]
  • [Cites] Genes Dev. 2001 Jun 15;15(12):1481-6 [11410528.001]
  • [Cites] EMBO J. 2001 Nov 15;20(22):6180-90 [11707390.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(24):8428-36 [11713278.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(13):4929-42 [12052897.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1716-21 [12657613.001]
  • [Cites] EMBO J. 2003 Jul 15;22(14):3686-95 [12853483.001]
  • [Cites] Sci STKE. 2004 Jun 29;2004(239):re9 [15226512.001]
  • (PMID = 19806201.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-jun; 0 / Transcription Factors; 0 / Tumor Necrosis Factor-alpha; 0 / proto-oncogene protein bcl-3; EC 2.7.1.24 / Mitogen-Activated Protein Kinase 9; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 8
  • [Other-IDs] NLM/ PMC2752166
  •  go-up   go-down


38. Jones M Pd Fiaca Faca: Dermatological effects from years in the sun: compounding opportunities. Int J Pharm Compd; 2006 Sep-Oct;10(5):336-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overexposure to the ultraviolet rays of the sun and tanning beds is a major cause of skin damage and the main cause of precancerous and cancerous skin lesions.
  • Unless detected and treated, actinic keratosis can progress to skin cancer.
  • The three main types of skin cancer are basal cell carcinoma, squamous cell carcinoma, and melanoma.
  • A number of treatment options are available for skin cancers, including topical preparations, systemic chemotherapy, photodynamic therapy, and surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23974311.001).
  • [ISSN] 1092-4221
  • [Journal-full-title] International journal of pharmaceutical compounding
  • [ISO-abbreviation] Int J Pharm Compd
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Imiquimod: new indication. Basal cell carcinoma: inferior to other treatments. Prescrire Int; 2006 Aug;15(84):130-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod: new indication. Basal cell carcinoma: inferior to other treatments.
  • (1) Basal cell carcinoma is a common malignancy that is rarely life-threatening.
  • The main alternative is radiotherapy. (2) The Indications section of the Summary of Product Characteristics (SPC) for imiquimod cream in Europe now includes "topical treatment of small superficial basal cell carcinomas in adults". (3) Imiquimod cream was primarily evaluated in 2 double-blind randomised controlled trials versus excipient, in a total of 724 patients.
  • In these trials, small basal cell tumours (maximum 2 cm in diameter) disappeared in three-quarters of patients after imiquimod application 5 or 7 days a week for six weeks. (4) A non comparative trial involving 143 patients showed a relapse rate of 21% at 2 years.
  • Indirect comparisons show that this is a much higher relapse rate than after other well-assessed treatments for basal cell cancer. (5) During clinical trials, nearly one-third of patients who used imiquimod 5 times a week complained of pruritus, a burning sensation, or local pain.
  • [MeSH-major] Aminoquinolines. Carcinoma, Basal Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989024.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments
  •  go-up   go-down


40. Bariani RL, Nahas FX, Barbosa MV, Farah AB, Ferreira LM: Basal cell carcinoma: an updated epidemiological and therapeutically profile of an urban population. Acta Cir Bras; 2006 Mar-Apr;21(2):66-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma: an updated epidemiological and therapeutically profile of an urban population.
  • PURPOSE: To describe the epidemiological profile of basal cell carcinoma patients at a private hospital in São Paulo and to evaluate the treatment adopted.
  • METHODS: A prospective study of 202 patients, on which 253 lesions were diagnosed for histopathological exam as basal cell carcinoma within the period of January 2001 to September 2003, in the Plastic Surgery Residency Program at the Hospital Jaraguá.
  • RESULTS: The incidence of basal cell carcinoma was 126 cases per 100,000 patients in a period of 32 months (36 cases per 100,000 patients/year).
  • Actinic keratosis and a history of skin cancer were reported in 43.6% and in 25% of the cases, respectively.
  • CONCLUSIONS: The factors related to the development of basal cell cancer which were significantly present in the population surveyed were: older age, white individuals, phototypes I and II, presence of actinic keratosis, previous history of non-melanoma skin cancer and exposure to ultra-violet rays both in recreational and in occupational form.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583057.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


41. Gerstenblith MR, Shi J, Landi MT: Genome-wide association studies of pigmentation and skin cancer: a review and meta-analysis. Pigment Cell Melanoma Res; 2010 Oct;23(5):587-606
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide association studies of pigmentation and skin cancer: a review and meta-analysis.
  • Recent genome-wide association studies (GWAS) identified genetic loci associated with pigmentation, nevi, and skin cancer.
  • We performed a review and meta-analysis of GWAS results, grouping them into four categories: (i) loci associated with pigmentation (hair, eye, and/or skin color), cutaneous UV-response (sun sensitivity and/or freckling), and skin cancer;.
  • (iii) loci associated with pigmentation and/or cutaneous UV-response but not skin cancer; and (iv) loci associated distinctly with skin cancer, mostly basal cell carcinoma, but not pigmentation or cutaneous UV-response.
  • These findings suggest at least two pathways for melanoma development (via pigmentation and via nevi), and two pathways for basal cell carcinoma development (via pigmentation and independent of pigmentation).
  • However, further work is necessary to separate the association with skin cancer from the association with pigmentation.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1260-6 [10922411.001]
  • [Cites] Hum Mol Genet. 2001 Jan 1;10(1):55-62 [11136714.001]
  • [Cites] Am J Hum Genet. 2008 Feb;82(2):424-31 [18252222.001]
  • [Cites] Hum Genet. 2008 Mar;123(2):177-87 [18172690.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2753-60 [18366057.001]
  • [Cites] PLoS Genet. 2008 May;4(5):e1000074 [18483556.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):838-40 [18488026.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):886-91 [18488027.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):835-7 [18488028.001]
  • [Cites] Hum Mutat. 2008 Sep;29(9):1161-7 [18563784.001]
  • [Cites] Hum Mutat. 2008 Sep;29(9):1154-60 [18683857.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):743-54 [18813320.001]
  • [Cites] Nat Genet. 2008 Nov;40(11):1313-8 [18849993.001]
  • [Cites] Nat Genet. 2008 Dec;40(12):1407-9 [18978787.001]
  • [Cites] J Invest Dermatol. 2009 Feb;129(2):415-21 [18668136.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):221-7 [19151717.001]
  • [Cites] Am J Hum Genet. 2009 May;84(5):672-7 [19375057.001]
  • [Cites] Int J Cancer. 2009 Aug 15;125(4):909-17 [19384953.001]
  • [Cites] Exp Dermatol. 2009 Jul;18(7):634-42 [19320733.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):909-14 [19578363.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):920-5 [19578364.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):915-9 [19578365.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):899-904 [19578367.001]
  • [Cites] J Invest Dermatol. 2009 Sep;129(9):2250-7 [19340012.001]
  • [Cites] Am J Hum Genet. 2009 Nov;85(5):679-91 [19836008.001]
  • [Cites] J Invest Dermatol. 2010 Feb;130(2):520-8 [19710684.001]
  • [Cites] PLoS Biol. 2010 Jan;8(1):e1000294 [20126254.001]
  • [Cites] Nat Genet. 2010 Mar;42(3):224-8 [20101243.001]
  • [Cites] Cancer Causes Control. 2009 Oct;20(8):1291-302 [19396635.001]
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):176-86 [10631149.001]
  • [Cites] J Invest Dermatol. 2001 Feb;116(2):224-9 [11179997.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):884-94 [11254446.001]
  • [Cites] Cutis. 2001 May;67(5):427-30 [11381862.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Aug;31(4):398-401 [11433531.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):686-94 [11455001.001]
  • [Cites] J Invest Dermatol. 2001 Aug;117(2):294-300 [11511307.001]
  • [Cites] Oncogene. 2001 Sep 6;20(39):5543-7 [11571653.001]
  • [Cites] Am J Hum Genet. 2002 Mar;70(3):770-5 [11833005.001]
  • [Cites] J Hum Genet. 2002;47(2):92-4 [11916009.001]
  • [Cites] Hum Mol Genet. 2002 May 15;11(11):1273-9 [12019208.001]
  • [Cites] Stat Med. 2002 Jun 15;21(11):1539-58 [12111919.001]
  • [Cites] Pigment Cell Res. 2003 Jun;16(3):287-96 [12753403.001]
  • [Cites] Arch Dermatol. 2003 Jun;139(6):816-7 [12810525.001]
  • [Cites] Med Pediatr Oncol. 2003 Aug;41(2):179-80 [12825234.001]
  • [Cites] Am J Hum Genet. 2003 Aug;73(2):301-13 [12844286.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):802-10 [12920225.001]
  • [Cites] Annu Rev Genet. 2003;37:67-90 [14616056.001]
  • [Cites] J Med Genet. 2004 Feb;41(2):e13 [14757863.001]
  • [Cites] Am J Hum Genet. 2004 Nov;75(5):739-51 [15372380.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2004 Nov 15;131C(1):75-81 [15452859.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1823-8 [3978567.001]
  • [Cites] N Engl J Med. 1989 May 25;320(21):1367-72 [2716782.001]
  • [Cites] Acta Oncol. 1993;32(6):621-2 [8260178.001]
  • [Cites] Hum Mol Genet. 1996 Oct;5(10):1663-6 [8894704.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2298-303 [9622062.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3245-51 [10506626.001]
  • [Cites] Hum Mutat. 2005 Mar;25(3):278-84 [15714523.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 6;97(13):998-1007 [15998953.001]
  • [Cites] Eur J Hum Genet. 2005 Aug;13(8):913-20 [15889046.001]
  • [Cites] Pigment Cell Res. 2005 Dec;18(6):393-410 [16280005.001]
  • [Cites] Science. 2005 Dec 16;310(5755):1782-6 [16357253.001]
  • [Cites] J Invest Dermatol. 2006 Jul;126(7):1510-7 [16645598.001]
  • [Cites] J Invest Dermatol. 2006 Aug;126(8):1842-9 [16601669.001]
  • [Cites] J Invest Dermatol. 2006 Aug;126(8):1691-2 [16845407.001]
  • [Cites] Hum Mol Genet. 2006 Oct 15;15(20):2975-9 [16928783.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9818-28 [17047042.001]
  • [Cites] Eur J Hum Genet. 2007 Jan;15(1):94-102 [17063143.001]
  • [Cites] Am J Hum Genet. 2007 Feb;80(2):241-52 [17236130.001]
  • [Cites] PLoS Genet. 2007 Jan 26;3(1):e17 [17257055.001]
  • [Cites] Mol Biol Evol. 2007 Mar;24(3):710-22 [17182896.001]
  • [Cites] Hum Mutat. 2007 May;28(5):495-505 [17279550.001]
  • [Cites] Am J Hum Genet. 2007 Dec;81(6):1119-32 [17999355.001]
  • [Cites] Nat Genet. 2007 Dec;39(12):1443-52 [17952075.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1179-89 [18083106.001]
  • [Cites] Am J Hum Genet. 2008 Feb;82(2):411-23 [18252221.001]
  • (PMID = 20546537.001).
  • [ISSN] 1755-148X
  • [Journal-full-title] Pigment cell & melanoma research
  • [ISO-abbreviation] Pigment Cell Melanoma Res
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Intramural; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS214020; NLM/ PMC3179913
  •  go-up   go-down


42. De La Torre-Lugo EM, Figueroa LD, Sánchez JL, Morales-Burgos A, Conde D: Skin cancer in Puerto Rico: a multiannual incidence comparative study. P R Health Sci J; 2010 Sep;29(3):312-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer in Puerto Rico: a multiannual incidence comparative study.
  • BACKGROUND: The incidence of skin cancer continues to increase worldwide.
  • The purpose of this study was to determine the incidence of skin cancer in Puerto Rico in a selected year (2005) and to compare these findings with those previously reported for Puerto Rico in 1974 and 1981 and with other countries.
  • The rate and distribution of the main types of skin cancer was calculated based on sex, age, anatomic location and laterality.
  • RESULTS: The incidence of skin cancer in Puerto Rico for 2005 was 6,568 cases, which represent a rate of 167.9 per 100,000 inhabitants.
  • The most common type of skin cancer was basal-cell carcinoma.
  • Skin cancer was more common in males except for melanoma, which was more common in females.
  • The incidence increases with age on all types of skin cancer.
  • CONCLUSIONS: We found an increasing incidence of skin cancer in Puerto Rico when compared with previous reported data.
  • This analysis provides a comprehensive evaluation of the epidemiology of skin cancer in Puerto Rico.
  • [MeSH-major] Skin Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20799521.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Puerto Rico
  •  go-up   go-down


43. Radespiel-Tröger M, Meyer M, Pfahlberg A, Lausen B, Uter W, Gefeller O: Outdoor work and skin cancer incidence: a registry-based study in Bavaria. Int Arch Occup Environ Health; 2009 Feb;82(3):357-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outdoor work and skin cancer incidence: a registry-based study in Bavaria.
  • OBJECTIVE: To analyse the association between occupational ultraviolet (UV) light exposure and skin cancer (basal cell carcinoma, BCC; squamous cell carcinoma, SCC; cutaneous malignant melanoma, CMM) based on data from the Bavarian population-based cancer registry.
  • METHODS: The population-based cancer registry of Bavaria (Germany) provided data on incident cases of BCC, SCC, and CMM, respectively, during the period 2001 until 2005.
  • Eleven Bavarian districts with complete skin cancer registration were included in this analysis based on 2,156,336 person years.
  • We computed age-specific and age-adjusted incidence rates of BCC (n = 1,641), SCC (n = 499), and CMM (n = 454) by work type, and the relative risk (RR) of skin cancer occurrence for "outdoor" and "mixed indoor/outdoor" workers, respectively, compared to "indoor" workers.
  • [MeSH-major] Neoplasms, Radiation-Induced / epidemiology. Occupational Diseases / etiology. Occupational Exposure. Registries. Skin Neoplasms / etiology. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Female. Germany / epidemiology. Humans. Incidence. Male. Melanoma / epidemiology. Melanoma / etiology. Middle Aged. Occupations. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649084.001).
  • [ISSN] 1432-1246
  • [Journal-full-title] International archives of occupational and environmental health
  • [ISO-abbreviation] Int Arch Occup Environ Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Schwartz JL, Kopecky KJ, Mathes RW, Leisenring WM, Friedman DL, Deeg HJ: Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. Radiat Res; 2009 Feb;171(2):155-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation.
  • Previous studies identified radiation therapy as a key modifier of basal cell carcinoma (BCC) risk in survivors of hematopoietic cell transplantation (HCT).

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Res. 1987 Jun;110(3):458-67 [3588850.001]
  • [Cites] Int J Radiat Biol. 1990 Apr;57(4):809-27 [1969909.001]
  • [Cites] J Am Acad Dermatol. 1990 May;22(5 Pt 1):859-60 [2347978.001]
  • [Cites] Radiat Res. 1991 Mar;125(3):318-25 [2000456.001]
  • [Cites] Med Pediatr Oncol. 1991;19(6):508-10 [1961139.001]
  • [Cites] Int J Hematol. 1993 Dec;59(1):67-71 [8161737.001]
  • [Cites] Health Phys. 1995 Jul;69(1):93-101 [7790217.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jun;5(6):419-24 [8781736.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1848-53 [8961975.001]
  • [Cites] N Engl J Med. 1997 Mar 27;336(13):897-904 [9070469.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1833-44 [9490664.001]
  • [Cites] Blood. 1998 May 15;91(10):3637-45 [9572999.001]
  • [Cites] Cancer Causes Control. 1998 Aug;9(4):393-401 [9794171.001]
  • [Cites] Ann ICRP. 1998;28(1-2):1-157 [10406427.001]
  • [Cites] Ann Plast Surg. 2004 Dec;53(6):593-5 [15602259.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3733-41 [15923570.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):444-53 [16344316.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1119-26 [16461782.001]
  • [Cites] Arch Dermatol. 2000 Aug;136(8):1007-11 [10926736.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1224-9 [11122025.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] Radiat Res. 2002 Apr;157(4):410-8 [11893243.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):634-8 [15373766.001]
  • [Cites] Radiat Res. 1985 Jun;102(3):378-91 [4070552.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):411-4 [3791154.001]
  • (PMID = 19267540.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102542-05; United States / NCI NIH HHS / CA / R01 CA102542-04; United States / NCI NIH HHS / CA / CA18029; United States / NHLBI NIH HHS / HL / HL36444; United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / P30 CA015704; United States / NCI NIH HHS / CA / CA102542-03; United States / NCI NIH HHS / CA / R01 CA102542-05; United States / NCI NIH HHS / CA / CA102542; United States / NCI NIH HHS / CA / R01 CA102542; United States / NCI NIH HHS / CA / CA102542-02; United States / NCI NIH HHS / CA / R01 CA102542-01A1; United States / NCI NIH HHS / CA / CA102542-04; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / CA102542-01A1; United States / NCI NIH HHS / CA / R01 CA102542-03; United States / NHLBI NIH HHS / HL / P01 HL036444; United States / NCI NIH HHS / CA / R01 CA102542-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS93674; NLM/ PMC2662700
  •  go-up   go-down


45. Geller AC, Brooks DR, Colditz GA, Koh HK, Frazier AL: Sun protection practices among offspring of women with personal or family history of skin cancer. Pediatrics; 2006 Apr;117(4):e688-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sun protection practices among offspring of women with personal or family history of skin cancer.
  • OBJECTIVE: Family history of skin cancer is an important determinant of skin cancer risk for offspring.
  • No previous study of the effect of personal or family history of skin cancer on the sun protection behaviors of the offspring has been published.
  • Adolescents' surveys were matched with their mothers' reports of a personal or family history of skin cancer and compared with adolescents whose mothers did not report a personal or family history of skin cancer.
  • The outcome measures were (1) occurrence of frequent sunburns during the past summer, (2) use of a tanning bed during the past year, and (3) routine use of sunscreen.
  • General estimating equations were used to calculate odds ratios and 95% confidence intervals adjusted for gender, age, color of untanned skin, and number of friends who were tanned.
  • We also conducted an additional analysis restricted to children whose mothers had received a diagnosis of skin cancer in which we assessed sun protection behaviors according to the child's age and mother's age at the time of the mother's diagnosis and the number of years that had passed since the diagnosis of the mother's skin cancer.
  • RESULTS: In 1999, 9943 children reported their sun protection behaviors; 8697 of their mothers had not received a diagnosis of skin cancer or reported a family history of melanoma, 463 participants' mothers had received a diagnosis of skin cancer, and 783 participants' mothers reported a family history of melanoma.
  • Between 1989 and 1999, 371 mothers of GUTS participants received a diagnosis of skin cancer: melanoma (n = 44), squamous cell (n = 39), and basal cell cancer (n = 311); 23 mothers received a diagnosis of > 1 type of skin cancer.
  • Because GUTS includes siblings from the same family, the 371 mothers with skin cancer had 463 offspring in GUTS.
  • Offspring of mothers with skin cancer were slightly more likely to report frequent sunburns in the past year compared with those with neither maternal diagnosis nor family history (39% vs 36%).
  • Tanning bed use was not significantly different among those with either a maternal diagnosis of skin cancer or family history of melanoma as compared with nonaffected adolescents (8% vs 9% vs 10%).
  • Sunscreen use among offspring of mothers with skin cancer was higher than among those whose mothers had a family history of melanoma or mothers with no personal history of skin cancer (42% vs 33% vs 34%).
  • Only 25% thought that a natural skin color was most attractive, and on average, 25% in each group agreed that it was worth burning to get a tan.
  • CONCLUSION: Frequent sunburns, suboptimal sunscreen use, and high rates of tanning bed use are commonplace even among the children of health professionals who are at risk for developing skin cancer themselves as a result of personal or family history.
  • With new information on family risk, pediatricians can use the potential of a teachable moment to ensure optimal sun protection for children who are at risk.
  • [MeSH-major] Adolescent Behavior. Health Behavior. Skin Neoplasms / genetics. Sunburn / prevention & control. Sunscreening Agents / administration & dosage
  • [MeSH-minor] Adolescent. Attitude to Health. Beauty Culture. Child. Female. Humans. Male. Melanoma / genetics. Radiation Protection. Skin Pigmentation

  • MedlinePlus Health Information. consumer health - Child Behavior Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16585282.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA93683-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


46. Gambichler T, Orlikov A, Vasa R, Moussa G, Hoffmann K, Stücker M, Altmeyer P, Bechara FG: In vivo optical coherence tomography of basal cell carcinoma. J Dermatol Sci; 2007 Mar;45(3):167-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo optical coherence tomography of basal cell carcinoma.
  • BACKGROUND: Optical coherence tomography (OCT) is a promising non-invasive imaging technique that has not systematically been studied in skin cancer such as basal cell carcinoma (BCC).
  • METHODS: Prior to the excision, the BCCs (n=43) as well as adjacent non-lesional skin sites were assessed by OCT in vivo.
  • RESULTS: Compared to non-lesional skin, a loss of normal skin architecture and disarrangement of the epidermis and upper dermis was observed in the OCT images of BCCs.
  • CONCLUSIONS: OCT is capable to visualize altered skin architecture and histopathological correlates of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Skin Neoplasms / diagnosis. Tomography, Optical Coherence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17215110.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


47. Wetzig T, Woitek M, Eichhorn K, Simon JC, Paasch U: Surgical excision of basal cell carcinoma with complete margin control: outcome at 5-year follow-up. Dermatology; 2010;220(4):363-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision of basal cell carcinoma with complete margin control: outcome at 5-year follow-up.
  • BACKGROUND: The incidence of skin cancer and especially basal cell carcinoma (BCC) has increased in the last few decades.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Microsurgery / methods. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20484877.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


48. Marrot L, Planel E, Ginestet AC, Belaïdi JP, Jones C, Meunier JR: In vitro tools for photobiological testing: molecular responses to simulated solar UV of keratinocytes growing as monolayers or as part of reconstructed skin. Photochem Photobiol Sci; 2010 Apr;9(4):448-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro tools for photobiological testing: molecular responses to simulated solar UV of keratinocytes growing as monolayers or as part of reconstructed skin.
  • Epidermal keratinocytes are critical targets for UV-induced genotoxicity as their transformation by sunlight overexposure can lead to skin cancer such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • Here, the same normal human keratinocytes either in monoculture (KC) or in full thickness reconstructed skin (RS) were compared with respect to their response to simulated solar UV (SSUV) exposure.
  • While in KC p53 accumulation displayed a linear dose-dependency up to 24 h post-exposure, in RS it followed a bell-shaped profile and reverted to its basal rate.
  • [MeSH-major] Keratinocytes / cytology. Keratinocytes / radiation effects. Photobiology / methods. Skin / cytology. Skin / growth & development. Ultraviolet Rays / adverse effects
  • [MeSH-minor] 3T3 Cells. Adult. Animals. Cell Culture Techniques. Cell Differentiation. Cell Proliferation / radiation effects. DNA Breaks / radiation effects. Dimerization. Dose-Response Relationship, Radiation. Female. Fibroblasts / cytology. Fibroblasts / metabolism. Fibroblasts / radiation effects. Gene Expression Profiling. Gene Expression Regulation / radiation effects. Humans. Kinetics. Mice. Oxidative Stress / radiation effects. Thymine / metabolism. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354637.001).
  • [ISSN] 1474-9092
  • [Journal-full-title] Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
  • [ISO-abbreviation] Photochem. Photobiol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; QR26YLT7LT / Thymine
  •  go-up   go-down


49. Katoh M, Katoh M: Transcriptional regulation of WNT2B based on the balance of Hedgehog, Notch, BMP and WNT signals. Int J Oncol; 2009 May;34(5):1411-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • WNT2B is expressed in several types of human cancer, such as basal cell carcinoma, gastric cancer, breast cancer, head/neck squamous cell carcinoma, cervical cancer and leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19360354.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Bone Morphogenetic Proteins; 0 / Glycoproteins; 0 / Hedgehog Proteins; 0 / Receptors, Notch; 0 / WNT2B protein, human; 0 / Wnt Proteins
  •  go-up   go-down


50. Zur Hausen H: The search for infectious causes of human cancers: where and why. Virology; 2009 Sep 15;392(1):1-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The search for infectious causes of human cancers: where and why.
  • Slightly more than 20% of the global cancer burden can presently be linked to infectious agents, including viruses, bacteria and parasites.
  • This manuscript analyzes reasons for their relatively late discovery and highlights epidemiological observations that may point to an involvement of additional infectious agents in specific human cancers.
  • Emphasis is placed on hematopoietic malignancies, breast and colorectal cancers, but also basal cell carcinomas of the skin and lung cancers in non-smokers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19720205.001).
  • [ISSN] 1096-0341
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Publication-type] Lectures
  • [Publication-country] United States
  •  go-up   go-down


51. Wang S, Basson MD: Integrin-linked kinase: a multi-functional regulator modulating extracellular pressure-stimulated cancer cell adhesion through focal adhesion kinase and AKT. Cell Oncol; 2009;31(4):273-89
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrin-linked kinase: a multi-functional regulator modulating extracellular pressure-stimulated cancer cell adhesion through focal adhesion kinase and AKT.
  • Cell adhesion is important in cancer metastasis.
  • Malignant cells in cancer patients may be exposed to physical forces such as extracellular pressure and shear, that stimulate their adhesion to matrix proteins, endothelium and surgical wounds.
  • Pressure induces phosphorylation of AKT and focal adhesion kinase (FAK), which are required for pressure-stimulated cancer cell adhesion, but what mediates this effect is unknown.
  • ILK may influence cell adhesion and FAK and AKT phosphorylation in other settings.
  • We therefore hypothesized that ILK might also regulate pressure-stimulated cancer cell adhesion through AKT and FAK phosphorylation.
  • Silencing ILK by siRNA reduced basal cancer cell adhesion and prevented the stimulation of adhesion by pressure.
  • ILK may be a key mediator of mechanotransduced signals in cancer cells and an important therapeutic target to inhibit metastatic cancer cell adhesion.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633364.001).
  • [ISSN] 1875-8606
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / 2R01DK060771
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.1.- / integrin-linked kinase; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC4619106
  •  go-up   go-down


52. Katoh M: WNT2B: comparative integromics and clinical applications (Review). Int J Mol Med; 2005 Dec;16(6):1103-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human WNT2B isoform 2 and other vertebrate WNT2B orthologs are canonical WNTs to determine cell fate through the activation of beta-catenin/TCF signaling pathway and SNAIL/EMT signaling pathway.
  • WNT2B functions as the stem cell factor for neural or retinal progenitor cells during embryogenesis, and also for gastric cancer, esophageal cancer and skin basal cell carcinoma during carcinogenesis.
  • Anti-WNT2B monoclonal antibody could be applied as selection marker of stem cells in the field of stem cell biology.
  • Soluble WNT2B protein or small molecule WNT2B mimic compounds could be developed for stem cell expansion in the fields of tissue engineering and regenerative medicine.
  • Anti-WNT2B monoclonal antibodies, WNT2B RNAi compounds, or small molecule WNT2B inhibitors could be developed as novel therapeutic agents for gastric cancer and esophageal cancer in the field of clinical oncology.

  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273293.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / WNT2B protein, human; 0 / Wnt Proteins
  • [Number-of-references] 99
  •  go-up   go-down


53. Euvrard S: [Skin cancers after organ transplants]. Presse Med; 2008 Oct;37(10):1475-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin cancers after organ transplants].
  • [Transliterated title] Cancers cutanés après greffe d'organe.
  • Squamous cell carcinoma and basal cell carcinoma are the most common cancers after transplants, affecting more than half of all patients in the long term.
  • In the 5 years after a first squamous cell carcinoma, 90 to 100% of transplant patients subsequently develop multiple skin carcinomas of various types and at least 20% develop noncutaneous cancers.
  • New immunosuppressants that inhibit the m-TOR protein (sirolimus and everolimus) appear to offer promising perspectives, and patients treated with these drugs from the time of their transplantation have fewer skin cancers than patients with the standard protocols.
  • Several prospective French multicenter studies are currently assessing the effect of replacing anticalcineurins by sirolimus or everolimus for secondary prevention of skin cancers in renal or cardiac transplant patients who have already developed skin cancer.
  • [MeSH-major] Organ Transplantation / adverse effects. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18775633.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 12
  •  go-up   go-down


54. Khaled A, Ben Mbarek L, Zeglaoui F, Ezzine N, Fazaa B, Kamoun MR: [Epidemiologic study of cutaneous cancers in aged persons]. Tunis Med; 2008 Oct;86(10):895-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiologic study of cutaneous cancers in aged persons].
  • [Transliterated title] Etude épidémiologique des cancers cutanés chez les sujets âgés.
  • Consequently, the number of aged patients with cutaneous cancer will increase in coming years.
  • OBJECTIVE: The objective was to determine the nature of skin cancer occurring in elderly patients.
  • METHODS: We retrospectively assessed all patients of 65 years of age and over, with histologically documented skin cancer, in the department of Dermatology of Charles Nicolle hospital of Tunis between 2000 and 2005.
  • RESULTS: 246 patients aged 65 years and over and presenting cutaneous cancers were collected.
  • They represented 57.34% of all cutaneous cancers.
  • Basal cell carcinoma (BCC) represented 68.2% of all cutaneous cancers in aged persons and 53.84% of all BCC independently of age.
  • Squamous cell carcinoma (SCC) represented 23.5% of all cutaneous cancers in aged persons and 67.44% of all SCC independently of age.
  • CONCLUSION: More than half of the collected cutaneous cancers during these 5 previous years have occurred in aged persons with a majority between the ages of 70 and 85 years.
  • [MeSH-major] Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472808.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


55. Koljonen V, Kukko H, Tukiainen E, Böhling T, Sankila R, Joensuu H, Pukkala E: Second cancers following the diagnosis of Merkel cell carcinoma: a nationwide cohort study. Cancer Epidemiol; 2010 Feb;34(1):62-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second cancers following the diagnosis of Merkel cell carcinoma: a nationwide cohort study.
  • Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma of the skin.
  • MCCs and some other skin cancers, such as basal cell carcinomas, frequently harbour Merkel cell polyomavirus DNA.
  • The purpose of the study was to investigate the frequency of second cancers following the diagnosis of MCC.
  • We studied the incidence of second primary cancers after the diagnosis of MCC from the files of the Finnish Cancer Registry in 1979-2006.
  • Among the 172 MCC patients identified a total of 34 second primary cancers were detected in 30 individuals after the diagnosis of MCC.
  • Female MCC patients were diagnosed with 25 subsequent cancers (SIR, 2.35; 95% CI, 1.52-3.47; p<0.001) and male patients with 9 cancers (SIR, 2.32, 95% CI, 1.06-4.40; p<0.05).
  • The MCC patients had an increased risk for a subsequent cancer (any site) compared to age-, gender- and calendar period-matched general population (standardized incidence ratio [SIR] 2.34; 95% confidence interval [CI], 1.62-3.27).
  • The risks for basal cell carcinoma of the skin (O=11), SIR, 3.48; 95% CI, 1.74-6.22 and chronic lymphocytic leukemia (O=2), SIR, 17.9; 95% CI, 2.16-64.6 were significantly elevated.
  • The SIRs for an overall second primary cancer risk did not change markedly with time since the diagnosis of MCC.
  • We conclude that patients diagnosed with MCC have an increased risk for a second cancer.
  • This risk may in part result from shared etiological factors between MCC and other tumour types, such as immunosuppression or possibly Merkel cell polyomavirus infection.
  • [MeSH-major] Carcinoma, Merkel Cell / epidemiology. Neoplasms, Second Primary / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / epidemiology. Cohort Studies. Female. Finland / epidemiology. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061203.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


56. Barth RN, Janus CA, Lillesand CA, Radke NA, Pirsch JD, Becker BN, Fernandez LA, Thomas Chin L, Becker YT, Odorico JS, D'Alessandro AM, Sollinger HW, Knechtle SJ: Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int; 2006 Nov;19(11):885-92
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.
  • No serious infectious complications were observed and two patients developed basal cell skin cancer.
  • Because of the higher incidence of early rejection, we recommend a modified strategy of immunosuppression including a brief course of a calcineurin inhibitor.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Transpl Int. 2006 Nov;19(11):881-4 [17018122.001]
  • (PMID = 17018123.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00365846
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Calcineurin Inhibitors; 0 / Immunosuppressive Agents; 3A189DH42V / alemtuzumab; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


57. Bulliard JL, Panizzon RG, Levi F: [Epidemiology of epithelial skin cancers]. Rev Med Suisse; 2009 Apr 22;5(200):882, 884-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology of epithelial skin cancers].
  • [Transliterated title] Epidémiologie des cancers épithéliaux de la peau.
  • With no less than 15,000 estimated new cases diagnosed per year, non melanomatous carcinomas are the commonest cutaneous cancers in the Swiss population.
  • About 1 in 3 new cancer case is a basal (BCC) or a squamous cell carcinoma (SCC).
  • Systematic population-based registration of non melanomatous skin cancers faces many challenges that few cancer registries can meet.
  • Rates of these cancers in Switzerland are among the highest in Europe.
  • Primary and secondary nationwide prevention campaigns have been carried out for nearly 20 years with a focus on the deadliest cutaneous cancer: melanoma.
  • However, detection of non melanomatous skin cancers benefits from these campaigns since prevention messages and means of early detection are similar for melanomas and other skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438088.001).
  • [ISSN] 1660-9379
  • [Journal-full-title] Revue médicale suisse
  • [ISO-abbreviation] Rev Med Suisse
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 31
  •  go-up   go-down


58. Boyd S, Tolvanen K, Virolainen S, Kuivanen T, Kyllönen L, Saarialho-Kere U: Differential expression of stromal MMP-1, MMP-9 and TIMP-1 in basal cell carcinomas of immunosuppressed patients and controls. Virchows Arch; 2008 Jan;452(1):83-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of stromal MMP-1, MMP-9 and TIMP-1 in basal cell carcinomas of immunosuppressed patients and controls.
  • Basal cell cancer (BCC) is the most common human malignancy.
  • Our results suggest that abundant peritumoral expression of TIMP-1 in non-immunocompromised patients limits ECM degradation permissive for cancer cell migration.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Immunocompromised Host. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 9 / metabolism. Skin Neoplasms / metabolism. Tissue Inhibitor of Metalloproteinase-1 / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18034264.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


59. Asplund A, Sivertsson A, Bäckvall H, Ahmadian A, Lundeberg J, Ponten F: Genetic mosaicism in basal cell carcinoma. Exp Dermatol; 2005 Aug;14(8):593-600
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic mosaicism in basal cell carcinoma.
  • Human basal cell cancer (BCC) shows unique growth characteristics, including a virtual inability to metastasize, absence of a precursor stage and lack of tumour progression.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Cell Transformation, Neoplastic. Mosaicism. Neoplasms, Glandular and Epithelial / genetics. Receptors, Androgen / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026581.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 109400
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Receptors, Androgen; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA
  •  go-up   go-down


60. Phillips D: Light relief: photochemistry and medicine. Photochem Photobiol Sci; 2010 Dec;9(12):1589-96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Photomedicine as a 'modern' subject began in the late 1880's, and currently encompasses the effects of light upon the skin, diagnostic uses of light, therapies using non-laser light, and the use of lasers.
  • Effects of light on the skin include production of Vitamin D, tanning, ageing of the skin, and the skin cancers basal cell and squamous cell carcinomas, and malignant melanoma.
  • Diagnostic uses of light include luminescence [photo and chemi] in immunoassays, fluorescence in cell sorting, and the various forms of fluorescence microscopy, including confocal, fluorescence lifetime imaging [FLIM], and single molecule.
  • Strategies to achieve this highlighted here are the use of monoclonal antibody fragments selected for tumour cell targets, and two-photon spatial selection.
  • [MeSH-minor] Antibodies, Monoclonal / chemistry. Humans. Lasers. Photochemotherapy. Photosensitizing Agents / chemistry. Skin Diseases / diagnosis. Skin Diseases / drug therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21082123.001).
  • [ISSN] 1474-9092
  • [Journal-full-title] Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
  • [ISO-abbreviation] Photochem. Photobiol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Photosensitizing Agents
  •  go-up   go-down


61. Paoli J, Smedh M, Ericson MB: Multiphoton laser scanning microscopy--a novel diagnostic method for superficial skin cancers. Semin Cutan Med Surg; 2009 Sep;28(3):190-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiphoton laser scanning microscopy--a novel diagnostic method for superficial skin cancers.
  • The increasing incidence of skin cancer and the importance of early diagnosis is a challenge, which requires the development of reliable, cost-effective, noninvasive, diagnostic techniques.
  • When studying human skin, MPLSM provides high-resolution fluorescence imaging, allowing visualization of cellular and subcellular structures of the epidermis and upper dermis.
  • This review covers the application of MPLSM as a diagnostic tool for superficial skin cancers, such as basal cell carcinomas, squamous cell carcinoma in situ, and melanomas.
  • MPLSM has also been applied in other research areas related to skin, which will be mentioned briefly.
  • The morphologic features observed in MPLSM images of skin tumors are comparable to traditional histopathology.
  • Although further investigations are required to make MPLSM a mainstream clinical diagnostic tool, MPLSM has the potential of becoming a noninvasive, bedside, histopathologic technique for the diagnosis of superficial skin cancers.
  • [MeSH-major] Microscopy, Confocal / methods. Microscopy, Fluorescence, Multiphoton / methods. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19782943.001).
  • [ISSN] 1558-0768
  • [Journal-full-title] Seminars in cutaneous medicine and surgery
  • [ISO-abbreviation] Semin Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


62. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C, IMPACT 2 Study Group: Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis; 2007 Apr;66(4):498-505
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two malignancies occurred: basal cell skin cancer (placebo) and stage I Hodgkin's lymphoma (infliximab).

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Psoriatic Arthritis.
  • MedlinePlus Health Information. consumer health - Psoriatic Arthritis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Infliximab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1999 Nov;113(5):752-9 [10571730.001]
  • [Cites] Arthritis Rheum. 1996 Dec;39(12):2013-20 [8961906.001]
  • [Cites] Lancet. 2000 Jul 29;356(9227):385-90 [10972371.001]
  • [Cites] Arthritis Rheum. 2001 Apr;45(2):151-8 [11324779.001]
  • [Cites] J Rheumatol. 2001 Aug;28(8):1842-6 [11508587.001]
  • [Cites] Arthritis Rheum. 2002 Oct 15;47(5):506-12 [12382299.001]
  • [Cites] Ann Rheum Dis. 2004 Jul;63(7):755-8 [15194567.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2264-72 [15248226.001]
  • [Cites] J Rheumatol. 1997 Mar;24(3):518-23 [9058659.001]
  • [Cites] J Invest Dermatol. 1997 Oct;109(4):562-5 [9326391.001]
  • [Cites] Arthritis Rheum. 1997 Oct;40(10):1868-72 [9336423.001]
  • [Cites] Arthritis Rheum. 1998 Jun;41(6):1103-10 [9627021.001]
  • [Cites] J Rheumatol. 1998 Aug;25(8):1544-52 [9712099.001]
  • [Cites] Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-7 [15708927.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1227-36 [15818699.001]
  • [Cites] Ann Rheum Dis. 2005 Aug;64(8):1150-7 [15677701.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2721-9 [16081850.001]
  • [Cites] Br J Dermatol. 2005 Sep;153(3):531-6 [16120138.001]
  • [Cites] J Am Acad Dermatol. 2005 Oct;53(4):573 [16198775.001]
  • [Cites] Arthritis Rheum. 2005 Oct;52(10):3279-89 [16200601.001]
  • [Cites] Ann Rheum Dis. 2006 Apr;65(4):471-7 [16096330.001]
  • [Cites] Mayo Clin Proc. 1978 Aug;53(8):511-8 [682678.001]
  • [Cites] Dermatologica. 1978;157(4):238-44 [357213.001]
  • [Cites] J Rheumatol. 1982 Sep-Oct;9(5):789-93 [7175852.001]
  • [Cites] Q J Med. 1987 Feb;62(238):127-41 [3659255.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Clin Exp Immunol. 1994 Apr;96(1):146-51 [8149659.001]
  • [Cites] Arthritis Rheum. 1995 Jun;38(6):727-35 [7779114.001]
  • [Cites] J Rheumatol. 2000 May;27(5):1247-50 [10813295.001]
  • (PMID = 17114188.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; B72HH48FLU / Infliximab
  • [Other-IDs] NLM/ PMC1856065
  •  go-up   go-down


63. Quatresooz P, Piérard-Franchimont C, Piérard GE: [Impact of the HIV infection on skin cancers]. Rev Med Liege; 2009 Jan;64(1):37-40
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of the HIV infection on skin cancers].
  • [Transliterated title] Impact de l'infection par le VIH sur les cancers cutanés.
  • A series of skin cancers are more frequent or show a worse course and outcome in HIV-treated patients.
  • The leading neoplasms correspond to basal and squamous cell carcinomas, some primary cutaneous lymphomas and malignant melanomas.
  • [MeSH-major] Carcinoma, Basal Cell / complications. Carcinoma, Squamous Cell / complications. HIV Infections / complications. Melanoma / complications. Skin Neoplasms / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317100.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 46
  •  go-up   go-down


64. Fontaine J, Mielczarek S, Meaume S, Senet P: [Incidence of undiagnosed skin cancers in a geriatric hospital]. Ann Dermatol Venereol; 2008 Oct;135(10):651-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence of undiagnosed skin cancers in a geriatric hospital].
  • [Transliterated title] Fréquence des cancers cutanés non diagnostiqués en hôpital gériatrique.
  • BACKGROUND: The incidence of non melanoma skin cancers is closely correlated with age.
  • The aim of this prospective study was to evaluate the prevalence of undiagnosed skin cancers among patients hospitalized in rehabilitation and long-term care units in a geriatric hospital.
  • Clinical data included patient age at the time of the study, gender, relevant historical information, skin phototype and description of the cutaneous lesions.
  • Skin phototype was clear for 93.5% of the patients.
  • Thirty-two out of 306 patients (10.5%) presented 42 suspicious lesions and these were diagnosed by histological examination as 16 basal-cell carcinomas, seven squamous cell-carcinomas and two in situ melanomas.
  • Skin cancers were localised on the head and neck in 80% of cases.
  • The prevalence of patients with skin cancers was 5.6% in this population.
  • CONCLUSION: The prevalence of skin cancers among patients hospitalized in geriatric hospitals justifies improved training of geriatricians regarding early recognition and dermatological assessment of cutaneous tumours.
  • [MeSH-major] Skin Neoplasms / diagnosis. Skin Neoplasms / epidemiology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / epidemiology. Cross-Sectional Studies. Female. France / epidemiology. Hospitalization. Humans. Long-Term Care. Male. Melanoma / diagnosis. Melanoma / epidemiology. Middle Aged. Prevalence. Prospective Studies. Rehabilitation Centers

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Dermatol Venereol. 2008 Oct;135(10):641-3 [18929911.001]
  • (PMID = 18929913.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


65. Quatresooz P, Piérard GE, Paquet P, Blaise G, Piérard-Franchimont C: [Cutaneous cancers after organ transplantation]. Rev Med Liege; 2007 Nov;62(11):663-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous cancers after organ transplantation].
  • [Transliterated title] Cancers cutanés après transplantation d'organe, un revers de médaille.
  • The usual squamous to basal cell carcinoma ratio is increased and reversed compared to the general population.
  • Carcinomas primarily result from the combination of cumulative sun exposure, fair skin phototype and effects of immunosuppressive drugs.
  • [MeSH-major] Immunosuppression / adverse effects. Immunosuppressive Agents / adverse effects. Organ Transplantation. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18217642.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 43
  •  go-up   go-down


66. Fadare O, Tavassoli FA: Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol; 2008 Mar;5(3):149-59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathologic aspects of basal-like breast cancers.
  • Gene-expression profiling of breast cancers has shown that distinct molecular subclasses are present within tumors that are apparently morphologically similar.
  • The molecular subclasses of cohorts classified by the 'intrinsic' gene set include the luminal A and B, erbB-2+, normal-breast-like, and basal-like tumors.
  • Basal-like breast cancers have been reported to be associated with worse overall and disease-free survival compared with the luminal A subtype.
  • In addition, there is an immunohistochemical surrogate for the basal-like profile, which has considerably facilitated their study in non-specialty laboratories.
  • Basal-like breast carcinomas have markedly reduced expression of genes related to estrogen receptors and erbB-2, and express proteins that are characteristic of the normal myoepithelial cell.
  • This Review appraises the current state of knowledge on the clinical and pathologic features of breast cancers classified as 'basal-like' by gene-expression profiling and/or immunohistochemical criteria.
  • Similarly to tumors of luminal epithelial differentiation, carcinomas of the 'basal' type have a spectrum of morphologic and clinical characteristics.
  • [MeSH-minor] Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Female. Gene Expression Profiling. Genes, BRCA1. Germ-Line Mutation. Humans. Neoplasm Invasiveness. Neoplasms, Basal Cell / drug therapy. Neoplasms, Basal Cell / genetics. Neoplasms, Basal Cell / pathology. Phenotype. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212769.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 100
  •  go-up   go-down


67. Choi J, Choo J, Chung H, Gweon DG, Park J, Kim HJ, Park S, Oh CH: Direct observation of spectral differences between normal and basal cell carcinoma (BCC) tissues using confocal Raman microscopy. Biopolymers; 2005 Apr 5;77(5):264-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct observation of spectral differences between normal and basal cell carcinoma (BCC) tissues using confocal Raman microscopy.
  • Raman spectroscopy has strong potential for providing noninvasive dermatological diagnosis of skin cancer.
  • In this study, confocal Raman microscopy was applied to the dermatological diagnosis for one of the most common skin cancers, basal cell carcinoma (BCC).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin / cytology. Skin / pathology. Skin Neoplasms / pathology. Spectrum Analysis, Raman

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 15657894.001).
  • [ISSN] 0006-3525
  • [Journal-full-title] Biopolymers
  • [ISO-abbreviation] Biopolymers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Eller MS, Asarch A, Gilchrest BA: Photoprotection in human skin--a multifaceted SOS response. Photochem Photobiol; 2008 Mar-Apr;84(2):339-49
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photoprotection in human skin--a multifaceted SOS response.
  • Human skin has developed elaborate defense mechanisms for combating a wide variety of potentially damaging environmental factors; principal among these is UV light.
  • Despite these defenses, short-term damage may include painful sunburn and long-term UV damage results in both accelerated skin aging and skin cancers such as basal cell carcinoma, squamous cell carcinoma and even malignant melanoma.
  • The following sections briefly review UV-inducible protective responses in bacteria and in skin, thymidine dinucleotides (pTT) as a powerful probe of DNA damage responses, and potential means of harnessing these inducible responses therapeutically to reduce the now enormous burden of cutaneous photodamage in our society.
  • [MeSH-major] SOS Response (Genetics). Skin / radiation effects
  • [MeSH-minor] Animals. DNA Damage. Humans. Neoplasms, Radiation-Induced / genetics. Skin Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179622.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 10515
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 140
  •  go-up   go-down


69. Stratigos AJ, Kapranos N, Petrakou E, Anastasiadou A, Pagouni A, Christofidou E, Petridis A, Papadopoulos O, Kokka E, Antoniou C, Georgala S, Katsambas AD: Immunophenotypic analysis of the p53 gene in non-melanoma skin cancer and correlation with apoptosis and cell proliferation. J Eur Acad Dermatol Venereol; 2005 Mar;19(2):180-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic analysis of the p53 gene in non-melanoma skin cancer and correlation with apoptosis and cell proliferation.
  • BACKGROUND: Sunlight precipitates a series of genetic events that lead to the development of skin cancers such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • The p53 tumour suppressor gene, which plays a pivotal role in cell division and apoptosis, is frequently found mutated in sunlight-induced skin tumours.
  • OBJECTIVE: To investigate the immunoreactivity of the p53 gene in non-melanoma skin cancers and to correlate its expression with apoptotic and cell proliferation markers.
  • METHODS: We analysed 35 non-melanoma tumours including 19 BCCs and 16 SCCs from sun-exposed skin areas. p53 protein expression was studied immunohistochemically using the DO7 monoclonal antibody against wild-type and mutant p53 forms.
  • Cell proliferation and apoptosis were also assessed by image analysis following Ki-67 immunostaining and application of the TUNEL method on paraffin sections, respectively.
  • Conversely, the TUNEL assay showed sporadic staining of apoptotic cells within the tumours with a mean value of 1.12% in BCCs and 1.8% in SCCs. p53 protein expression was correlated positively with cell proliferation (r = 0.75, P = 0.000001) and negatively with apoptosis (r = -0.23, P = 0.05).
  • CONCLUSION: p53 immunoreactivity was high in the majority of the skin carcinomas examined and correlated positively with cell proliferation and negatively with apoptosis.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Genes, p53 / genetics. Skin Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Aged. Apoptosis. Cell Division. Female. Humans. Immunohistochemistry. Immunophenotyping. Male. Mutation. Sunlight

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752287.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


70. Akyol M, Ozçelik S: Non-acne dermatologic indications for systemic isotretinoin. Am J Clin Dermatol; 2005;6(3):175-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diseases such as psoriasis, pityriasis rubra pilaris, condylomata acuminata, skin cancers, rosacea, hidradenitis suppurativa, granuloma annulare, lupus erythematosus and lichen planus have been shown to respond to the immunomodulatory, anti-inflammatory and antitumor activities of the drug.
  • Isotretinoin also helps prevent skin cancers such as basal cell carcinoma or squamous cell carcinoma.
  • A combination of systemic isotretinoin and interferon-alpha-2a may provide a more potent effect than isotretinoin alone in the prevention and treatment of skin cancers.Systemic isotretinoin may be considered as an alternative drug in some dermatologic diseases unresponsive to conventional treatment modalities.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Dermatologic Agents / therapeutic use. Isotretinoin / therapeutic use. Skin Diseases / drug therapy
  • [MeSH-minor] Acne Vulgaris / drug therapy. Anti-Bacterial Agents / therapeutic use. Condylomata Acuminata / drug therapy. Drug Therapy, Combination. Granuloma Annulare / drug therapy. Hidradenitis Suppurativa / drug therapy. Humans. Keratolytic Agents / therapeutic use. Lichen Planus / drug therapy. Lupus Erythematosus, Systemic / drug therapy. Pityriasis Rubra Pilaris / drug therapy. Psoriasis / drug therapy. Rosacea / drug therapy. Sebaceous Glands / drug effects. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943494.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Dermatologic Agents; 0 / Keratolytic Agents; EH28UP18IF / Isotretinoin
  • [Number-of-references] 133
  •  go-up   go-down


71. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, Reis-Filho JS, Smalley MJ: BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell; 2010 Sep 3;7(3):403-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.
  • Breast cancers in BRCA1 mutation carriers frequently have a distinctive basal-like phenotype.
  • It has been suggested that this results from an origin in basal breast epithelial stem cells.
  • Here, we demonstrate that deleting Brca1 in mouse mammary epithelial luminal progenitors produces tumors that phenocopy human BRCA1 breast cancers.
  • They also resemble the majority of sporadic basal-like breast tumors.
  • However, directing Brca1 deficiency to basal cells generates tumors that express molecular markers of basal breast cancers but do not histologically resemble either human BRCA1 or the majority of sporadic basal-like breast tumors.
  • These findings support a derivation of the majority of human BRCA1-associated and sporadic basal-like tumors from luminal progenitors rather than from basal stem cells.
  • This has important implications for cancer prevention strategies.


72. Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, Narod SA, Hanna WM: Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat; 2009 Nov;118(1):131-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
  • Traditional prognostic markers for breast cancer include estrogen receptor (ER), progesterone receptor (ER) and HER2/neu.
  • By adding markers for cytokeratin 5/6 and EGFR, triple-negative breast cancers can be divided into 'basal-like' and 'normal-like' subgroups.
  • We conducted immuno-staining on a panel of 958 patients with breast cancer, using all five markers and we followed the patients for distal recurrence and death.
  • We compared rates of distal recurrence in the basal-like and normal-like subgroups with that of women with ER-positive breast cancer.
  • Only 16 of 958 women had normal-like breast cancers.
  • These cancers resembled basal-like cancers in that they had a high proliferative index, but the women with normal-like breast cancers resembled ER-positive women in terms of distant recurrence.
  • The addition of CK5/6 and EGFR to the standard panel (ER/PR/HER2/neu) defines a small subgroup of women with normal-like breast cancer.
  • The prognosis of these women may be superior to that of basal-like breast cancers but firm conclusions cannot be made.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Division. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Keratin-5 / analysis. Keratin-6 / analysis. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Metastasis. Prognosis. Proportional Hazards Models. Receptor, Epidermal Growth Factor / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19189211.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Keratin-5; 0 / Keratin-6; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


73. Fadare O, Tavassoli FA: The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol; 2007 Sep;14(5):358-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The phenotypic spectrum of basal-like breast cancers: a critical appraisal.
  • There are 2 well-recognized cell populations lining the mammary duct system: the epithelial cells lining the lumen and the myoepithelial cells surrounding them.
  • The mammary stem cell, a putative third cell type, has not yet been well characterized.
  • It is not established whether the putative stem cell expresses the full complement, a subset, or none of the markers of normal epithelial and/or myoepithelial cells.
  • All 3 cell types may theoretically undergo malignant transformation.
  • The advent of oligonucleotide and cDNA microarrays has facilitated gene expression profiling of breast cancers, revealing molecular subclasses that may be prognostically relevant.
  • One such subclass, the basal-like breast carcinomas, has been found in numerous independent datasets to be associated with a comparatively worse overall and disease-free survival.
  • These cancers show expression of molecules characteristic of the normal myoepithelial cell, such as basal cytokeratins, and reduced expression of estrogen receptor-related and Erb-B2-related genes and proteins.
  • The classifier genes that formed the basis for the delineation of basal-like carcinomas were derived from datasets that were composed predominantly of ductal type cancers.
  • Therefore, the clinical significance of a basal-like gene expression or immunohistochemical profile in the other breast cancer subtypes is presently unknown.
  • Herein, we evaluate in detail the current state of knowledge on the pathologic features of breast carcinomas classified as basal-like by immunohistochemical and/or gene expression profiling criteria, with an emphasis on their full phenotypic spectrum and also previously underemphasized areas of heterogeneity and ambiguity where present.
  • There seems to be a phenotypic and biologic spectrum of basal-like or myoepithelial-type carcinomas, just as there is a wide range among tumors of luminal epithelial derivation/differentiation.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Neoplasms, Basal Cell / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717437.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 153
  •  go-up   go-down


74. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Buttarelli M, Jacquemier J, Chaffanet M, Maraninchi D, Viens P, Birnbaum D: How different are luminal A and basal breast cancers? Int J Cancer; 2009 Mar 15;124(6):1338-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How different are luminal A and basal breast cancers?
  • Heterogeneity of breast cancer makes its evolution difficult to predict, and its treatment far from being optimal.
  • Two major subtypes are luminal A and basal subtypes, which have opposite features, notably survival.
  • To characterize these 2 subtypes better, with the hope of better understanding their different biology and clinical outcome, we have profiled a series of 138 tumours (80 luminal A and 58 basal) using Affymetrix whole-genome DNA microarrays.
  • Genes associated with proliferation, cell cycle, cell motility, angiogenesis, and NFkB signalling were overexpressed in basal tumours.
  • The number of differentially expressed genes was as high as the set of genes discriminating 2 cancers of different anatomical origin (breast and colon) or discriminating acute myeloid and lymphoid leukaemia.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19058218.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Neoplasm; 0 / Receptors, Estrogen
  •  go-up   go-down


75. Chen MH, Yip GW, Tse GM, Moriya T, Lui PC, Zin ML, Bay BH, Tan PH: Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters. Mod Pathol; 2008 Oct;21(10):1183-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters.
  • Previous studies have suggested that breast cancer in young women has more aggressive biological features and poorer prognosis.
  • We aimed to learn more about this disease in a cohort of 125 young women from Singapore, Japan and Hong Kong, aged 35 years or less, with invasive breast cancer by evaluating the expression of vimentin and the basal cytokeratins CK14, CK5/6 and 34 beta E12.
  • Basal cytokeratins and vimentin showed significant inverse relationship with estrogen and progesterone receptor status while CK14 expression was found to be directly associated with c-erbB2 status.
  • Basal cytokeratins and vimentin immunoreactivities were directly associated with CD117 and EGFR expression.
  • Our findings are in concert with reports that expression of basal cytokeratins and vimentin is correlated with adverse pathological parameters.
  • [MeSH-minor] Adult. Cell Line, Tumor. Cohort Studies. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18536655.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


76. Raouf A: Basal-like breast cancers: the phenotypic disparity between the cancer-initiating cells and tumor histology. Breast Cancer Res; 2010;12(6):316
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal-like breast cancers: the phenotypic disparity between the cancer-initiating cells and tumor histology.
  • Recent evidence suggests that a rare-cell population with a stem cell phenotype maintains breast tumors.
  • Therefore, to devise breast cancer therapies that are more effective, we need to understand the unique biology of these cancer stem cells.
  • Currently, very little is known about the origin of cancer stem cells and their relationship to the tumor phenotype.
  • A recent study from Smalley's group demonstrates that targeting an inactivating Brca1 mutation to the luminal progenitors could yield basal-like breast cancers.
  • [MeSH-major] Breast Neoplasms / pathology. Genes, BRCA1. Neoplasms, Basal Cell / pathology. Neoplastic Stem Cells / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Trends Endocrinol Metab. 2004 Jul;15(5):193-7 [15223047.001]
  • [Cites] Zentralbl Allg Pathol. 1985;130(4):323-31 [3911652.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Nature. 2006 Jan 5;439(7072):84-8 [16397499.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] Cell Stem Cell. 2008 Jul 3;3(1):109-18 [18593563.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1160-7 [19204204.001]
  • [Cites] Nat Med. 2009 Aug;15(8):907-13 [19648928.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jun;121(3):575-89 [19688261.001]
  • [Cites] Cell Stem Cell. 2010 Sep 3;7(3):403-17 [20804975.001]
  • (PMID = 21172068.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC3046428
  •  go-up   go-down


77. Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, Jones C, Lord CJ, Vatcheva R, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Reis-Filho JS: An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat; 2010 Jun;121(3):575-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.
  • Breast cancer is a heterogeneous disease caused by the accumulation of genetic changes in neoplastic cells.
  • We hypothesised that molecular subtypes of breast cancer may be driven by specific constellations of genes whose expression is regulated by gene copy number aberrations.
  • There were 5,931 genes whose expression significantly correlates with copy number identified; out of these, 1,897 genes were significantly differentially expressed between basal-like, HER2 and luminal tumours.
  • Ingenuity Pathway Analysis (IPA) revealed that 'G1/S cell cycle regulation' and 'BRCA1 in DNA damage control' pathways were significantly enriched for genes whose expression correlates with copy number and are differentially expressed between the molecular subtypes of breast cancer.
  • We also identified 32, 157 and 265 genes significantly overexpressed when amplified in basal-like, HER2 and luminal cancers, respectively.
  • HER2 and PPM1D in HER2 cancers).
  • Our results provide strong circumstantial evidence that different patterns of genetic aberrations in distinct molecular subtypes of breast cancer contribute to their specific transcriptomic profiles and that biological phenomena characteristic of each subtype (e.g. proliferation, HER2 and ER signalling) may be driven by specific patterns of copy number aberrations.


78. Quintela-Fandino M, Arpaia E, Brenner D, Goh T, Yeung FA, Blaser H, Alexandrova R, Lind EF, Tusche MW, Wakeham A, Ohashi PS, Mak TW: HUNK suppresses metastasis of basal type breast cancers by disrupting the interaction between PP2A and cofilin-1. Proc Natl Acad Sci U S A; 2010 Feb 9;107(6):2622-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HUNK suppresses metastasis of basal type breast cancers by disrupting the interaction between PP2A and cofilin-1.
  • Metastasis leads to the death of most cancer patients, and basal breast cancer is the most aggressive breast tumor type.
  • Metastasis involves a complex cell migration process dependent on cytoskeletal remodeling such that targeting such remodeling in tumor cells could be clinically beneficial.
  • Here we show that Hormonally Up-regulated Neu-associated Kinase (HUNK) is dramatically down-regulated in tumor samples and cell lines derived from basal breast cancers.
  • Reconstitution of HUNK expression in basal breast cancer cell lines blocked actin polymerization and reduced cell motility, resulting in decreased metastases in two in vivo murine cancer models.
  • HUNK reconstitution in basal breast cancer cell lines prevented protein phosphatase 2-A (PP2A), a phosphatase putatively acting on CFL-1, from binding to CFL-1.
  • Our investigation of HUNK suggests that the interaction between PP2A and CFL-1 may be a target for antimetastasis therapy, particularly for basal breast cancers.
  • [MeSH-minor] Actins / metabolism. Animals. Cell Line, Tumor. Cell Movement. Cytoskeleton / metabolism. Female. Humans. Immunoblotting. Immunoprecipitation. Male. Mammary Neoplasms, Experimental / genetics. Mammary Neoplasms, Experimental / metabolism. Mammary Neoplasms, Experimental / pathology. Melanoma, Experimental / genetics. Melanoma, Experimental / metabolism. Melanoma, Experimental / pathology. Mice. Mice, Inbred C57BL. Neoplasm Invasiveness. Neoplasm Metastasis. Phosphorylation. Protein Binding. RNA Interference. Transplantation, Heterologous


79. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH: Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol; 2010 Jun;176(6):2911-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
  • Although Wnt/beta-catenin pathway activation has been implicated in mouse models of breast cancer, there is contradictory evidence regarding its importance in human breast cancer.
  • In this study, invasive and in situ breast cancer tissue microarrays containing luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)(+)/ER(-) and basal-like breast cancers were analyzed for beta-catenin subcellular localization.
  • We demonstrate that nuclear and cytosolic accumulation of beta-catenin, a read-out of Wnt pathway activation, was enriched in basal-like breast cancers.
  • In contrast, membrane-associated beta-catenin was observed in all breast cancer subtypes, and its expression decreased with tumor progression.
  • Moreover, nuclear and cytosolic localization of beta-catenin was associated with other markers of the basal-like phenotype, including nuclear hormone receptor and HER2 negativity, cytokeratin 5/6 and vimentin expression, and stem cell enrichment.
  • In addition, beta-catenin accumulation was more often observed in basal-like in situ carcinomas than other in situ subtypes, suggesting that activation of this pathway might be an early event in basal-like tumor development.
  • Collectively, these data indicate that Wnt/beta-catenin activation is an important feature of basal-like breast cancers and is predictive of worse overall survival, suggesting that it may be an attractive pharmacological target for this aggressive breast cancer subtype.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):149-59 [18212769.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):989-97 [18281472.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R53 [18559090.001]
  • [Cites] Histol Histopathol. 2009 Mar;24(3):385-98 [19130408.001]
  • [Cites] PLoS One. 2009;4(3):e4968 [19319191.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4116-24 [19435916.001]
  • [Cites] Histopathology. 2000 Apr;36(4):313-25 [10759945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4262-6 [10759547.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Carcinogenesis. 2000 Nov;21(11):1935-40 [11062151.001]
  • [Cites] Eur J Surg Oncol. 2001 Feb;27(1):31-6 [11237489.001]
  • [Cites] J Pathol. 2001 Apr;193(4):433-41 [11276001.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):793-801 [11533658.001]
  • [Cites] J Pathol. 2002 Feb;196(2):145-53 [11793365.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):1087-97 [12213737.001]
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1281-6 [12439718.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2658-64 [12750294.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):145-58 [14635791.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):91-102 [14749129.001]
  • [Cites] Cancer. 2004 May 15;100(10):2084-92 [15139049.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12682-7 [15314234.001]
  • [Cites] Cell. 1987 Aug 14;50(4):649-57 [3111720.001]
  • [Cites] Cell. 1988 Nov 18;55(4):619-25 [3180222.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):7057-61 [2208173.001]
  • [Cites] J Clin Pathol. 1993 Feb;46(2):189-90 [8459046.001]
  • [Cites] Biometrics. 1994 Dec;50(4):933-44 [7787006.001]
  • [Cites] Virchows Arch. 1997 Sep;431(3):167-72 [9334837.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):75-82 [9422525.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Pathol. 1998 Jul;185(3):262-6 [9771479.001]
  • [Cites] J Cancer Res Clin Oncol. 1999;125(5):297-304 [10359135.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):1046-51 [10362114.001]
  • [Cites] Breast Cancer Res Treat. 2005 Apr;90(3):249-56 [15830138.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3585-94 [16105882.001]
  • [Cites] Mod Pathol. 2006 May;19(5):617-21 [16528377.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5487-94 [16707478.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1506-11 [16941011.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):618-23 [17202265.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):468-77 [17227796.001]
  • [Cites] J Pathol. 2007 Mar;211(4):389-98 [17212342.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2329-34 [17438091.001]
  • [Cites] J Mol Histol. 2007 May;38(2):113-21 [17318343.001]
  • [Cites] Cancer. 2007 May 1;109(9):1721-8 [17387718.001]
  • [Cites] Cells Tissues Organs. 2007;185(1-3):191-203 [17587825.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4038-44 [18593979.001]
  • (PMID = 20395444.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA125183; United States / NCI NIH HHS / CA / R03 CA132143; United States / NCI NIH HHS / CA / R03 CA132143-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Wnt Proteins; 0 / beta Catenin; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2877852
  •  go-up   go-down


80. Nseir A, Estève E: [Basal cell carcinoma]. Presse Med; 2008 Oct;37(10):1466-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell carcinoma].
  • Basal cell carcinoma (BCC) accounts for 80% of skin cancers, and its frequency is increasing substantially and regularly.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18687568.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 17
  •  go-up   go-down


81. Yu W, Kanaan Y, Bae YK, Gabrielson E: Chromosomal changes in aggressive breast cancers with basal-like features. Cancer Genet Cytogenet; 2009 Aug;193(1):29-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal changes in aggressive breast cancers with basal-like features.
  • Using high-resolution oligonucleotide comparative genomic hybridization arrays, we evaluated chromosomal copy number changes in a series of 16 breast cancers, selected on the basis of highly similar pathologic and molecular features characteristic of the "basal-like" phenotype.
  • Each of these cancers showed numerous gains and losses, reflecting multiple chromosomal rearrangements during the development of these high-grade cancers.
  • These regions included candidate oncogenes cKIT, JUND, and AKT2, and immunohistochemistry confirmed that these particular genes were highly expressed in the cancers harboring the specific amplifications.
  • Each of these amplifications was observed only in individual cases, however, and no particular chromosomal alteration appeared to generally characterize this group of cancers.
  • Thus, genomic changes among breast cancers with basal-like features appear to be very heterogeneous.
  • Distinct high-level amplifications may provide new targets for treating some of these cancers, but copy number changes do not reveal a distinctive genomic fingerprint for this proposed class of breast cancers.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Oct 28;18(44):6063-70 [10557095.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):831-6 [10879734.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Lab Invest. 2002 Nov;82(11):1525-33 [12429812.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):64-71 [14729609.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):178-83 [14734467.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5988-97 [15447982.001]
  • [Cites] Cancer. 1971 Feb;27(2):288-99 [4322462.001]
  • [Cites] Breast Cancer Res Treat. 1987 Oct;10(1):11-20 [2446682.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Mar;86(5):1500-3 [2493644.001]
  • [Cites] Oncogene. 1991 Apr;6(4):561-6 [1903194.001]
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):280-5 [7657393.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8534-40 [15574759.001]
  • [Cites] J Pathol. 2005 Oct;207(2):224-31 [16021678.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8085-9 [16166280.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R1186-98 [16457699.001]
  • [Cites] J Pathol. 2006 Mar;208(4):495-506 [16429394.001]
  • [Cites] Histopathology. 2006 Jul;49(1):22-34 [16842243.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Nov;45(11):1033-40 [16897746.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] Mol Cancer Res. 2006 Dec;4(12):927-34 [17189383.001]
  • [Cites] Cancer Cell. 2007 Apr;11(4):361-74 [17418412.001]
  • [Cites] Histopathology. 2007 Mar;50(4):434-8 [17448018.001]
  • [Cites] Adv Anat Pathol. 2007 Sep;14(5):358-73 [17717437.001]
  • [Cites] BMC Cancer. 2007;7:145 [17672916.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11565-75 [18089785.001]
  • [Cites] Breast Cancer Res. 2007;9(5):R65 [17910759.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1368-76 [18316557.001]
  • [ErratumIn] Cancer Genet Cytogenet. 2010 Apr 1;198(1):77. Baed, Young-Kyung [corrected to Bae, Young Kyung]
  • (PMID = 19602461.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA088843; United States / NCI NIH HHS / CA / P50CA088843; United States / NCI NIH HHS / CA / U54 CA091409-07; United States / NCI NIH HHS / CA / U54 CA091409; United States / NCI NIH HHS / CA / CA091409-08; United States / NCI NIH HHS / CA / U54CA091409; United States / NCI NIH HHS / CA / U54 CA091409-08; United States / NCI NIH HHS / CA / CA091409-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS135457; NLM/ PMC2768045
  •  go-up   go-down


82. Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen SØ, Foulkes WD, Akslen LA: A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev; 2005 May;14(5):1108-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors.
  • Interval breast cancer reduce the effectiveness of mammography screening programs.
  • We studied 95 interval cancers, diagnosed during 1996 to 2001 as part of the population-based Norwegian Breast Cancer Screening Program.
  • These cases were matched on size (+/-2.0 mm) to 95 screen-detected breast cancers, and the tumors were compared by immunohistochemical methods using tissue microarrays.
  • Patients with interval cancers were more likely to be younger [odds ratio (OR), 4.7; P = 0.0001], to have dense breasts (OR, 3.4; P = 0.004), and to have estrogen receptor-negative tumors (OR, 2.6, P = 0.01), and p53 expression was more frequent (OR, 4.0; P = 0.001).
  • Notably, interval cancers were more likely to have a basal epithelial phenotype, in that expression of cytokeratin 5/6 (OR, 2.3; P = 0.04) and P-cadherin (OR, 2.5; P = 0.04) was more frequent in interval cases than in size-matched, screen-detected tumors.
  • In a logistic regression model, p53 expression, age, and breast density were independent predictors of interval cancers.
  • Our data suggest that breast cancers with a basal epithelial phenotype are more likely than nonbasal breast cancers to present between regular mammograms.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / radiography. Carcinoma, Basal Cell / radiography. Mammography. Mass Screening / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894660.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Coloring Agents; 0 / Receptors, Estrogen; 68238-35-7 / Keratins
  •  go-up   go-down


83. Degen A, Satzger I, Voelker B, Kapp A, Hauschild A, Gutzmer R: Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? Dermatology; 2010;221(3):193-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?
  • Multiple cutaneous side effects are well described but recent reports indicated a possible association of epithelial skin cancer growth during sorafenib therapy.
  • To our knowledge, few cases of actinic keratoses and variants of squamous cell carcinomas associated with sorafenib have been published.
  • We report 2 patients who developed a basal cell carcinoma (BCC) while treated with sorafenib.
  • After termination of sorafenib treatment, no new BCCs or other epithelial skin cancers occurred.
  • There is accumulating evidence in the literature that sorafenib and possibly other targeted agents are associated with an increased occurrence of epithelial skin cancers.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Benzenesulfonates / adverse effects. Carcinoma, Basal Cell / chemically induced. Protein Kinase Inhibitors / adverse effects. Pyridines / adverse effects. Skin Neoplasms / chemically induced
  • [MeSH-minor] Aged. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Female. Humans. Male. Melanoma / drug therapy. Melanoma / secondary. Niacinamide / analogs & derivatives. Phenylurea Compounds

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20720388.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


84. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Fernö M, Isola J: Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res; 2007;9(1):R16
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.
  • INTRODUCTION: Basal-phenotype or basal-like breast cancers are characterized by basal epithelium cytokeratin (CK5/14/17) expression, negative estrogen receptor (ER) status and distinct gene expression signature.
  • We studied the clinical and biological features of the basal-phenotype tumors determined by immunohistochemistry (IHC) and cDNA microarrays especially within the ER-negative subgroup.
  • METHODS: IHC was used to evaluate the CK5/14 status of 445 stage II breast cancers.
  • Survival for basal-phenotype tumors as determined by CK5/14 IHC and gene expression signature was assessed.
  • Hierarchical clustering analysis with the top 500 of these genes formed one basal-like and a non-basal-like cluster also within the ER-negative tumor entity.
  • Both gene sets identified a basal-like cluster that included most of the CK5/14-positive tumors, but also immunohistochemically CK5/14-negative tumors.
  • Within the ER-negative tumor entity there was no survival difference between the non-basal and basal-like tumors as identified by immunohistochemical or gene-expression-based classification.
  • CONCLUSION: Basal cytokeratin-positive tumors have a biologically distinct gene expression signature from other ER-negative tumors.
  • Even if basal cytokeratin expression predicts early relapse among non-selected tumors, the clinical outcome of basal tumors is similar to non-basal ER-negative tumors.
  • Immunohistochemically basal cytokeratin-positive tumors almost always belong to the basal-like gene expression profile, but this cluster also includes few basal cytokeratin-negative tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 May;25(1):58-62 [10802657.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):122-32 [12884041.001]
  • [Cites] Bioinformatics. 2000 Nov;16(11):1038-9 [11159315.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5979-84 [11507038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11462-7 [11562467.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):e15 [11842121.001]
  • [Cites] Methods Mol Med. 2002;68:205-22 [11901504.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):737-46 [12065684.001]
  • [Cites] Genome Biol. 2002 Jul 15;3(8):SOFTWARE0003 [12186655.001]
  • [Cites] Lab Invest. 2002 Nov;82(11):1525-33 [12429812.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1991-6 [12466114.001]
  • [Cites] Breast Cancer Res. 2003;5(1):23-6 [12559041.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2406-15 [12855612.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] Cell Prolif. 2003 Oct;36 Suppl 1:73-84 [14521517.001]
  • [Cites] Acta Oncol. 2003;42(7):719-25 [14690157.001]
  • [Cites] J Pathol. 2004 Jun;203(2):661-71 [15141381.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):249-58 [15254720.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4793-8 [15269154.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6143-51 [15448001.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Breast Cancer Res Treat. 1987 Oct;10(1):11-20 [2446682.001]
  • [Cites] Am J Pathol. 1991 Mar;138(3):751-63 [1705754.001]
  • [Cites] Virchows Arch. 1998 Aug;433(2):119-29 [9737789.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] J Clin Pathol. 2004 Dec;57(12):1288-91 [15563669.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8682-7 [15574777.001]
  • [Cites] J Pathol. 2005 Aug;206(4):451-7 [15906273.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5678-85 [16115903.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1321-8 [15990899.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] Oncology. 2005;69(6):478-85 [16410686.001]
  • [Cites] J Pathol. 2006 Mar;208(4):495-506 [16429394.001]
  • [Cites] Brain Res. 2006 Feb 3;1071(1):226-36 [16409990.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1533-9 [16533778.001]
  • [Cites] J Clin Pathol. 2006 Jul;59(7):729-35 [16556664.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4185-91 [16857790.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • (PMID = 17263897.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-14; 0 / Keratin-5; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC1851391
  •  go-up   go-down


85. Arora A, Attwood J: Common skin cancers and their precursors. Surg Clin North Am; 2009 Jun;89(3):703-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common skin cancers and their precursors.
  • This review of precancerous and cancerous skin lesions serves as an overview for the general surgeon in clinical practice.
  • General surgeons have a unique role in caring for these common skin cancers both primarily and by understanding the basis for referral to a specialist.
  • With these goals in mind, we discuss the pathophysiology of cutaneous malignancy as well as the diagnosis and treatment of the three most common cutaneous malignancies in the United States: basal cell, squamous cell, and melanoma skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Melanoma / pathology. Precancerous Conditions. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465206.001).
  • [ISSN] 1558-3171
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


86. Watanabe S, Suzuki K, Asamura H: Superior and basal segment lung cancers in the lower lobe have different lymph node metastatic pathways and prognosis. Ann Thorac Surg; 2008 Mar;85(3):1026-31
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superior and basal segment lung cancers in the lower lobe have different lymph node metastatic pathways and prognosis.
  • The aim of this study was to reveal differences in the metastatic pathway to the mediastinum and in prognosis of N2 disease between lung cancers originating from superior and basal segment of the lower lobe.
  • METHODS: Data on 139 patients who underwent pulmonary resection with systematic nodal dissection for pN2 non-small cell lung cancer (NSCLC) originating from the lower lobe between 1980 and 2001 were retrospectively reviewed.
  • Those lower lobe N2 tumors were divided into two groups by origin: 51 were superior segment, and 88 were basal segment.
  • RESULTS: The superior segment group showed a significantly higher incidence of superior mediastinal metastasis than the basal segment group (64% vs 36%, p = 0.0012).
  • When superior mediastinal metastasis existed, the basal segment group showed a significantly higher incidence of synchronous subcarinal metastasis than the superior segment group (81% vs 39%, p = 0.0006).
  • Pneumonectomy was required significantly more often in the superior segment group than in the basal segment group (45% vs 17%, p = 0.0003).
  • The basal segment origin tumors with only subcarinal metastasis showed significantly better prognosis than other lower lobe N2 tumors (5-year survival, 43% vs 18%; p = 0.0155).
  • CONCLUSIONS: Basal segment tumor metastasizes to the superior mediastinum mostly through the subcarinal node, whereas superior segment tumors often metastasize directly to the superior mediastinum without concomitant metastasis to the subcarinal node.
  • As for the prognosis among lower lobe N2 tumors, only in cases with basal segment tumor without superior mediastinal metastasis may long-term survival be expected.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18291191.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


87. Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, Sotgia F, Brody JR, Mitchell EP, Lisanti MP: Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther; 2010 Jul 15;10(2):135-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.
  • Here, we investigated the possible predictive value of stromal caveolin-1 (Cav-1) as a candidate biomarker for clinical outcome in triple negative (TN) breast cancer patients.
  • A cohort of 85 TN breast cancer patients was available, with the necessary annotation and nearly 12 years of follow-up data.
  • As such, the prognostic value of Cav-1 immunostaining in TN breast cancer patients is compartment-specific, and selective for an absence of Cav-1 staining in the stromal fibroblast compartment.
  • A recursive-partitioning algorithm was used to assess which factors are most predictive of overall survival in TN breast cancer patients.
  • This analysis indicated that stromal loss of Cav-1 expression was the most important prognostic factor for overall survival in TN breast cancer.
  • Virtually identical results were obtained with CK5/6 (+) and/or EGFR (+) TN breast cancer cases, demonstrating that a loss of stromal Cav-1 is also a strong prognostic factor for basal-like breast cancers.
  • Our current findings may have important implications for the close monitoring and treatment stratification of TN and basal-like breast cancer patients.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cell Cycle. 2010 May 15;9(10):1960-71 [20495363.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):24745-56 [15044451.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Curr Top Pathol. 1970;53:161-220 [4323195.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1381-5 [7877987.001]
  • [Cites] Eur J Cancer. 2006 Dec;42(18):3149-56 [17055256.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R16 [17263897.001]
  • [Cites] Cancer. 2007 May 1;109(9):1721-8 [17387718.001]
  • [Cites] Breast Cancer Res. 2007;9(5):R65 [17910759.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1368-76 [18316557.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):2944-52 [18483361.001]
  • [Cites] Br J Cancer. 2008 Jul 22;99(2):327-34 [18612310.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5158-65 [18698033.001]
  • [Cites] Cancer Biol Ther. 2008 Aug;7(8):1212-25 [18458534.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2302-10 [19318481.001]
  • [Cites] Cell Cycle. 2009 Jun 1;8(11):1654-8 [19448435.001]
  • [Cites] Am J Pathol. 2009 Jun;174(6):2023-34 [19411448.001]
  • [Cites] Cancer Biol Ther. 2009 Jun;8(11):1071-9 [19502809.001]
  • [Cites] Cell Cycle. 2009 Dec;8(23):3984-4001 [19923890.001]
  • [Cites] J Pathol. 2004 Jun;203(2):661-71 [15141381.001]
  • (PMID = 20431349.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098779; United States / NCI NIH HHS / CA / R01-CA-120876; United States / NCI NIH HHS / CA / R01 CA120876; United States / NCI NIH HHS / CA / R01-CA-098779; United States / NIAMS NIH HHS / AR / R01-AR-055660; United States / NCI NIH HHS / CA / R01-CA-080250; United States / NIAMS NIH HHS / AR / R01 AR055660; United States / NCI NIH HHS / CA / R01 CA080250
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1; 0 / Keratin-5; 0 / Keratin-6; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC3040896
  •  go-up   go-down


88. Xie J: Molecular biology of basal and squamous cell carcinomas. Adv Exp Med Biol; 2008;624:241-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of basal and squamous cell carcinomas.
  • Basal cell carcinomas and Squamous cell carcinomas are the two most common human cancers.
  • The incidence of these two types of cancer is estimated to double within 20 years.
  • Identification of the key molecular events is critical in helping us design novel strategies to treat and to prevent these cancers.
  • For example, identification of hedgehog signaling activation has opened up many opportunities for targeted therapy and prevention of basal cell carcinomas.
  • Significant progress has also been made in our understanding of squamous cell carcinomas of the skin.
  • In this chapter, we will focus on major recent developments in our understanding of basal cell carcinomas and squamous cell carcinomas at the molecular levels and their clinical implications.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Molecular Biology. Mutation / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18348461.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA94160
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 85
  •  go-up   go-down


89. Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C, Achouri Y, Sotiropoulou PA, Blanpain C: Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol; 2010 Mar;12(3):299-305

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the cell lineage at the origin of basal cell carcinoma.
  • For most types of cancers, the cell at the origin of tumour initiation is still unknown.
  • Here, we used mouse genetics to identify cells at the origin of basal cell carcinoma (BCC), which is one of the most frequently occurring types of cancer in humans, and can result from the activation of the Hedgehog signalling pathway.
  • Using mice conditionally expressing constitutively active Smoothened mutant (SmoM2), we activated Hedgehog signalling in different cellular compartments of the skin epidermis and determined in which compartments Hedgehog activation induces BCC formation.
  • Activation of SmoM2 in hair follicle bulge stem cells and their transient amplifying progenies did not induce cancer formation, demonstrating that BCC does not originate from bulge stem cells, as previously thought.
  • Our studies uncover the cells at the origin of BCC in mice and demonstrate that expression of differentiation markers in tumour cells is not necessarily predictive of the cancer initiating cells.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Cell Lineage. Epidermis / pathology
  • [MeSH-minor] Animals. Bacterial Proteins / genetics. Bacterial Proteins / metabolism. Cadherins / metabolism. Cell Count. Cell Differentiation. Clone Cells / metabolism. Clone Cells / pathology. Ear, External / pathology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Genes, Reporter / genetics. Hair Follicle / metabolism. Hair Follicle / pathology. Hedgehog Proteins / genetics. Integrases / genetics. Integrin beta4 / metabolism. Keratin-10 / metabolism. Keratin-14 / genetics. Keratin-15 / genetics. Keratin-15 / metabolism. Keratin-19 / genetics. Kruppel-Like Transcription Factors / metabolism. Luminescent Proteins / genetics. Luminescent Proteins / metabolism. Mice. Mice, Inbred Strains. Mice, Transgenic. Models, Biological. Neoplastic Stem Cells / metabolism. Neoplastic Stem Cells / pathology. Proteins / genetics. Proteins / metabolism. RNA, Untranslated. Receptors, Cell Surface / metabolism. Receptors, G-Protein-Coupled / genetics. Receptors, G-Protein-Coupled / metabolism. Skin / metabolism. Skin / pathology. Tail / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cell Stem Cell. 2010 Apr 2;6(4):292-4 [20362530.001]
  • (PMID = 20154679.001).
  • [ISSN] 1476-4679
  • [Journal-full-title] Nature cell biology
  • [ISO-abbreviation] Nat. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Cadherins; 0 / Gt(ROSA)26Sor non-coding RNA, mouse; 0 / Hedgehog Proteins; 0 / Integrin beta4; 0 / Keratin-14; 0 / Keratin-15; 0 / Keratin-19; 0 / Krt1-10 protein, mouse; 0 / Krt1-14 protein, mouse; 0 / Krt1-15 protein, mouse; 0 / Kruppel-Like Transcription Factors; 0 / Luminescent Proteins; 0 / Proteins; 0 / RNA, Untranslated; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / Shh protein, mouse; 0 / Smo protein, mouse; 0 / patched receptors; 0 / yellow fluorescent protein, Bacteria; 147785-83-9 / Keratin-10; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  •  go-up   go-down


90. Erb P, Ji J, Wernli M, Kump E, Glaser A, Büchner SA: Role of apoptosis in basal cell and squamous cell carcinoma formation. Immunol Lett; 2005 Aug 15;100(1):68-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of apoptosis in basal cell and squamous cell carcinoma formation.
  • Long-term ultraviolet-light (UV) exposure of human skin epidermis is associated with an increased risk for the development of skin cancers, such as melanoma, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • UV radiation not only induces DNA damage in epidermal cells, it also interferes with skin homeostasis, which is maintained by a unique distribution pattern of apoptosis-inducing and -preventing molecules.
  • If the DNA damage is not repaired or the damaged cells are not eliminated by apoptosis, the consequence can be cell transformation, uncontrolled proliferation and eventually skin tumor formation.
  • Excessive UV exposure can mutate the p53 gene leading to the loss of its repair function and thus apoptosis resistance of the DNA-damaged cell.
  • Silencing the genes involved in tumor formation by RNA interference might become a promising new approach to treat skin tumors.
  • [MeSH-major] Apoptosis. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Gene Expression Regulation, Neoplastic / radiation effects. Signal Transduction / radiation effects. Skin Neoplasms / metabolism. Ultraviolet Rays / adverse effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054233.001).
  • [ISSN] 0165-2478
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Fasl protein, mouse; 0 / Hedgehog Proteins; 0 / Membrane Glycoproteins; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 24
  •  go-up   go-down


91. Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H: Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med; 2007 Mar;4(3):e90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
  • BACKGROUND: In breast cancers, only a minority of patients fully benefit from the different chemotherapy regimens currently in use.
  • In cell lines or animal models, tumor protein p53 (TP53) plays a critical role in modulating the response to genotoxic drugs.
  • TP53 is activated in response to DNA damage and triggers either apoptosis or cell-cycle arrest, which have opposite effects on cell fate.
  • Breast cancers with a TP53 mutation were repeatedly shown to have a poor outcome, but whether this reflects poor response to treatment or greater intrinsic aggressiveness of the tumor is unknown.
  • METHODS AND FINDINGS: In this study we analyzed 80 noninflammatory breast cancers treated by frontline (neoadjuvant) chemotherapy.
  • Tumor diagnoses were performed on pretreatment biopsies, and the patients then received six cycles of a dose-dense regimen of 75 mg/m(2) epirubicin and 1,200 mg/m(2) cyclophosphamide, given every 14 days.
  • Furthermore, among the TP53-mutant tumors, nine out of ten of the highly aggressive basal subtypes (defined by basal cytokeratin [KRT] immunohistochemical staining) experienced complete pathological responses, and only TP53 status and basal subtype were independent predictors of a complete response.
  • Expression analysis identified many mutant TP53-associated genes, including CDC20, TTK, CDKN2A, and the stem cell gene PROM1, but failed to identify a transcriptional profile associated with complete responses among TP53 mutant tumors.
  • CONCLUSIONS: This study demonstrates that, in noninflammatory breast cancers, TP53 status is a key predictive factor for response to this dose-dense epirubicin-cyclophosphamide regimen and further suggests that the basal subtype is exquisitely sensitive to this association.
  • Given the well-established predictive value of complete responses for long-term survival and the poor prognosis of basal and TP53-mutant tumors treated with other regimens, this chemotherapy could be particularly suited for breast cancer patients with a mutant TP53, particularly those with basal features.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1999 Dec 22;84(6):587-93 [10567903.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1504-11 [16968874.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(1):61-70 [11518467.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Breast Cancer Res Treat. 2001 Dec;70(3):205-12 [11804184.001]
  • [Cites] Lancet. 2002 Sep 14;360(9336):852-4 [12243922.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1991-6 [12466114.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1431-9 [12668651.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2600-8 [12829681.001]
  • [Cites] Lancet. 2003 Aug 2;362(9381):362-9 [12907009.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] Breast. 2003 Dec;12(6):522-8 [14659130.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1428-34 [15138159.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6548-58 [15221012.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6418-31 [15475428.001]
  • [Cites] Eur J Cancer. 1971 Feb;7(1):11-6 [5576726.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1580-9 [7888675.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3963-7 [7732013.001]
  • [Cites] Nat Med. 1996 Jul;2(7):811-4 [8673929.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):163-9 [9010218.001]
  • [Cites] Br J Cancer. 1998 Dec;78(12):1661-8 [9862580.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] J Clin Invest. 1999 Aug;104(3):223-5 [10430602.001]
  • [Cites] J Clin Invest. 1999 Aug;104(3):263-9 [10430607.001]
  • [Cites] Ann Oncol. 1999 Jul;10(7):795-801 [10470426.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):307-15 [15549092.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Ann Oncol. 2005 May;16(5):743-8 [15802278.001]
  • [Cites] Oncol Rep. 2005 Aug;14(2):513-20 [16012739.001]
  • [Cites] Cancer Cell. 2005 Jul;8(1):7-12 [16023594.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5678-85 [16115903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5 [16141321.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1157-67 [16489069.001]
  • [Cites] Breast Cancer Res Treat. 2006 Feb;95(3):229-33 [16322899.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1940-9 [16622270.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2428-36 [16682728.001]
  • [Cites] J Clin Pathol. 2006 Jul;59(7):729-35 [16556664.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10):1369-79 [16766179.001]
  • [Cites] Nature. 2006 Sep 14;443(7108):153-4 [16971934.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):50-6 [10656431.001]
  • (PMID = 17388661.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Databank-accession-numbers] RefSeq/ NM/ 000077/ NM/ 000125/ NM/ 000389/ NM/ 000422/ NM/ 000424/ NM/ 000546/ NM/ 001005862/ NM/ 001067/ NM/ 001124/ NM/ 001255/ NM/ 001809/ NM/ 001827/ NM/ 003311/ NM/ 003318/ NM/ 004336/ NM/ 004701/ NM/ 005556/ NM/ 006017/ NM/ 010755/ NM/ 014417/ NM/ 021992/ NM/ 031966/ NM/ 057212/ NM/ 058195/ NM/ 080747/ NM/ 138763/ NP/ 000068/ NP/ 000116/ NP/ 000380/ NP/ 000413/ NP/ 000415/ NP/ 001005862/ NP/ 001115/ NP/ 001246/ NP/ 001800/ NP/ 003302/ NP/ 003309/ NP/ 004692/ NP/ 005547/ NP/ 006008/ NP/ 006133/ NP/ 034885/ NP/ 055232/ NP/ 068832/ NP/ 114172/ NP/ 476560/ NP/ 478102/ NP/ 542785/ NP/ 620118
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC1831731
  •  go-up   go-down


92. Shemesh S, Spencer JM, Phelps RG: Pattern of development of basal versus squamous cell carcinoma. J Drugs Dermatol; 2006 Jan;5(1):40-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of development of basal versus squamous cell carcinoma.
  • BACKGROUND: Basal cell and squamous cell carcinomas both arise in the epidermis of fair-skinned people in response to ultraviolet light, with the overall frequency of basal cell carcinoma being 4 times that of squamous cell carcinoma.
  • OBJECTIVE: The study explores whether or not there is a pattern of expression of basal versus squamous cell carcinoma among people with these cancers.
  • METHODS: This case-control study involved patients with a total of more than 3 and fewer than 10 basal or squamous cell carcinomas.
  • Patient age and gender, as well as number and location of diagnosed basal and squamous cell carcinomas were gathered and patterns within these values were sought.
  • RESULTS: Patients found to have at least one basal cell carcinoma tended to produce more basal cell carcinomas and patients found to have at least one squamous cell carcinoma tended to produce more squamous cell carcinomas.
  • CONCLUSION: The study supports the possibility that people who develop basal cell carcinoma are more likely to develop more basal cell carcinomas.
  • Similarly, people who develop squamous cell carcinoma are more likely to develop more squamous cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468291.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Osiecka B, Jurczyszyn K, Symonowicz K, Bronowicz A, Ostasiewicz P, Czapińska E, Hotowy K, Krzystek-Korpacka M, Gebarowska E, Izykowska I, Dziegiel P, Terlecki G, Ziółkowski P: In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester. Cell Mol Biol Lett; 2010 Dec;15(4):630-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This therapy involves the application of a chemical called a photosensitizer and its subsequent excitation with light at the appropriate wavelength and energy.
  • Topical photodynamic therapy with aminolevulinic acid (5-ALA) is an alternative therapy for many malignant processes, including nonmelanoma skin cancers such as basal-cell carcinoma (BCC).
  • Our novel approach for this study was to use a liposomal formulation of 5-ALA and its methyl ester (commercially available as metvix) both in vitro and in vivo, and to check whether the liposome-entrapped precursors of photosensitizers can induce the expression of metalloproteinases (MMPs) in animal tumor cells and in other tissues from tumor-bearing rats and in selected cell lines in vitro.
  • The preliminary data obtained from cancer patients revealed that new precursors are effective in terms of PDT, and that using MMP inhibitors should be considered as a potential enhancing factor in clinical PDT.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Cell Line, Tumor / drug effects. Liposomes. Matrix Metalloproteinases / metabolism. Photochemotherapy / methods. Photosensitizing Agents
  • [MeSH-minor] Animals. Breast Neoplasms / drug therapy. Breast Neoplasms / enzymology. Breast Neoplasms / radiotherapy. Cell Survival / drug effects. Female. Humans. Isoenzymes / metabolism. Rats. Rats, Wistar. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20865364.001).
  • [ISSN] 1689-1392
  • [Journal-full-title] Cellular & molecular biology letters
  • [ISO-abbreviation] Cell. Mol. Biol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Liposomes; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


94. Desai A, Krathen R, Orengo I, Medrano EE: The age of skin cancers. Sci Aging Knowledge Environ; 2006 May 15;2006(9):pe13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The age of skin cancers.
  • Cancer affects two major cell types in the human skin: epithelial cells and melanocytes.
  • Aging and a previous history of ultraviolet light exposure are major risk factors for skin cancers, including basal and squamous cell carcinomas and melanomas.
  • However, melanomas, which are the most deadly of the skin tumors, display two intriguing characteristics: The incidence is increased and the prognosis is worse in males over 60 years as compared with females of the same age.
  • [MeSH-major] Carcinoma, Basal Cell / physiopathology. Carcinoma, Squamous Cell / physiopathology. Melanoma / physiopathology. Skin Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16723638.001).
  • [ISSN] 1539-6150
  • [Journal-full-title] Science of aging knowledge environment : SAGE KE
  • [ISO-abbreviation] Sci Aging Knowledge Environ
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Daya-Grosjean L, Couvé-Privat S: Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett; 2005 Jul 28;225(2):181-92
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonic hedgehog signaling in basal cell carcinomas.
  • The development of basal cell carcinoma, the commonest human cancer in fair skinned populations, is clearly associated with constitutive activation of sonic hedgehog signaling.
  • Insight into the genesis of BCC came from the identification of germline mutations of the tumor suppressor gene, PATCHED, a key regulatory component of hedgehog signaling in the nevoid basal cell carcinoma syndrome.
  • Analysis of sporadic basal cell carcinomas and those from repair deficient xeroderma pigmentosum patients has revealed mutational inactivation of PATCHED and gain of function mutations of the proto-oncogenes, SMOOTHENED and SONIC HEDGEHOG associated with solar UV exposure.
  • The molecular mechanisms involved in alterations of the hedgehog signaling pathway that lead to the formation of basal cell carcinomas are being unraveled and has already allowed the investigation of future therapeutic strategies for treating these skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Signal Transduction. Trans-Activators / metabolism

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15978322.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / SHH protein, human; 0 / Trans-Activators
  • [Number-of-references] 96
  •  go-up   go-down


96. Klingbeil P, Natrajan R, Everitt G, Vatcheva R, Marchio C, Palacios J, Buerger H, Reis-Filho JS, Isacke CM: CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Res Treat; 2010 Feb;120(1):95-109
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification.
  • Here we describe the identification of a high level amplification of human 11p13, encompassing the CD44 gene, in primary breast cancers and cell lines and test whether CD44 acts as the driver of this amplicon. aCGH analysis revealed 11p13 amplification in 3% (3/100) of primary breast carcinomas and in two cell lines.
  • Amplification was confirmed by dual-colour FISH in these cell lines and further validated by CISH in an independent tumour cohort.
  • CD44 expression in primary breast cancers was significantly associated with features of basal-like breast cancer.
  • Detection of CD44 expression in breast cancer cell lines confirmed moderate to high expression in basal-like cell lines and minimal expression in luminal cell lines.
  • In both, primary breast cancers and cell lines, 11p13 amplification was associated with high levels of CD44 mRNA expression.
  • CD44 alternative splicing was detected in four of nine cell lines and in tumour samples, irrespective of the amplification status.
  • RNAi mediated knock down of CD44 failed to reveal an increased dependence on CD44 expression for proliferation or survival in amplified cell lines.
  • [MeSH-minor] Alternative Splicing. Cell Line, Tumor. Comparative Genomic Hybridization. Female. Gene Amplification. Gene Dosage. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Neoplasm Staging. RNA, Small Interfering. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19350388.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / RNA, Small Interfering
  •  go-up   go-down


97. Bilal E, Alexe G, Yao M, Cong L, Kulkarni A, Ginjala V, Toppmeyer D, Ganesan S, Bhanot G: Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers. Genes Cancer; 2010 Oct;1(10):1063-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers.
  • Targeted cancer therapies aim to neutralize specific proteins that are necessary for the cancer cell to remain viable in vivo.
  • Using our method, we found that several SRC proto-oncogenes LYN, YES1, HCK, FYN, and LCK have high centrality in identifiable subsets of basal-like and HER2+ breast cancers.
  • To experimentally validate the clinical value of this finding, we evaluated the effect of YES1 knockdown in basal-like breast cancer cell lines that overexpress this gene.
  • We found that YES1 downregulation has a significant effect on the survival of these cell lines.
  • Our results identify YES1 as a target for therapeutics in a subset of basal-like breast cancers.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioinformatics. 2004 Jan 1;20(1):105-14 [14693816.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):671-9 [15721472.001]
  • [Cites] Exp Cell Res. 2005 Apr 1;304(2):604-19 [15748904.001]
  • [Cites] Acta Histochem. 2005;107(2):87-93 [15950051.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1283-98 [16564017.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] BMC Bioinformatics. 2006;7 Suppl 1:S7 [16723010.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10292-301 [17079448.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Breast Cancer Res Treat. 2007 Nov;105(3):319-26 [17268817.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2226-38 [17332353.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] BMC Bioinformatics. 2007;8:291 [17683614.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10669-76 [18006808.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1368-76 [18316557.001]
  • [Cites] Cancer Inform. 2006;2:243-74 [19458770.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Clin Oncol. 2010 Mar 1;28(7):1145-53 [20100965.001]
  • [Cites] Cancer Res. 2010 Mar 15;70(6):2296-306 [20215510.001]
  • [Cites] Mod Pathol. 2010 Nov;23(11):1499-506 [20693982.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1029-34 [7489358.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Br J Cancer. 1991 Apr;63(4):508-13 [2021534.001]
  • [Cites] Genetica. 2007 Jan;129(1):83-103 [16897451.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5979-84 [11507038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • (PMID = 21779430.001).
  • [ISSN] 1947-6027
  • [Journal-full-title] Genes & cancer
  • [ISO-abbreviation] Genes Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3092264
  • [Keywords] NOTNLM ; breast cancer / eigenvector centrality / oncogene / therapeutic target
  •  go-up   go-down


98. Papa G, Grandi G, Pascone M: Collision tumor of malignant skin cancers: a case of melanoma in basal cell carcinoma. Pathol Res Pract; 2006;202(9):691-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of malignant skin cancers: a case of melanoma in basal cell carcinoma.
  • The coexistence of two malignant skin tumors intermingling in the same histologic specimen is rare.
  • We report a case of melanoma in a basal cell carcinoma collision tumor.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, Neoplasm. Carcinoma, Squamous Cell / pathology. Cheek / pathology. Female. Humans. Immunohistochemistry. Melanoma-Specific Antigens. Neoplasm Proteins / metabolism. S100 Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876964.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


99. Holstege H, Horlings HM, Velds A, Langerød A, Børresen-Dale AL, van de Vijver MJ, Nederlof PM, Jonkers J: BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer; 2010;10:654
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
  • BACKGROUND: Basal-like breast cancers (BLBC) are aggressive breast cancers for which, so far, no targeted therapy is available because they typically lack expression of hormone receptors and HER2.


100. Karagas MR, Nelson HH, Sehr P, Waterboer T, Stukel TA, Andrew A, Green AC, Bavinck JN, Perry A, Spencer S, Rees JR, Mott LA, Pawlita M: Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst; 2006 Mar 15;98(6):389-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin.
  • BACKGROUND: Although infection with human papillomaviruses (HPVs) is a major risk factor for several epithelial cancers, an etiologic relationship between HPV and keratinocyte cancers, such as squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs), remains unclear.
  • Data on sun sensitivity, outdoor exposure, and other risk factors for keratinocyte cancers were collected through personal interviews.
  • [MeSH-major] Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / virology. Papillomaviridae. Papillomavirus Infections / complications. Skin Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2006 Oct 4;98(19):1425-6 [17018790.001]
  • (PMID = 16537831.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA57494
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement